121P SERUM CARCINOEMBRYONIC ANTIGEN LEVELS PREDICTS THE EFFICACY OF EGFR-TKI IN NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS (English)
- New search for: Zhang, Y.
- New search for: Han, B.
- New search for: Jin, B.
- New search for: Lou, Y.
- New search for: Li, R.
- New search for: Zhang, X.
- New search for: Hu, S.
- New search for: Zhang, Y.
- New search for: Han, B.
- New search for: Jin, B.
- New search for: Lou, Y.
- New search for: Li, R.
- New search for: Zhang, X.
- New search for: Hu, S.
In:
ANNALS OF ONCOLOGY
;
26
;
i38-i38
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:121P SERUM CARCINOEMBRYONIC ANTIGEN LEVELS PREDICTS THE EFFICACY OF EGFR-TKI IN NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS
-
Contributors:
-
Published in:ANNALS OF ONCOLOGY ; 26 ; i38-i38
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:i38-i38
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
thanks to referees 2014| 2015
- 7
-
Phase I trials in oncology: a new era has startedPostel-Vinay, S. / Soria, J. C. et al. | 2015
- 9
-
Challenges in combining novel molecularly targeted agents in cancer medicineYap, T. A. et al. | 2015
- 11
-
Pushing the boundaries of somatic copy-number variation detection: advances and challengesSathirapongsasuti, J. F. et al. | 2015
- 13
-
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsSorich, M. J. / Wiese, M. D. / Rowland, A. / Kichenadasse, G. / McKinnon, R. A. / Karapetis, C. S. et al. | 2015
- 21
-
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)†Maschmeyer, G. / Carratalà, J. / Buchheidt, D. / Hamprecht, A. / Heussel, C. P. / Kahl, C. / Lorenz, J. / Neumann, S. / Rieger, C. / Ruhnke, M. et al. | 2015
- 33
-
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevanceKhoja, L. / Lorigan, P. / Dive, C. / Keilholz, U. / Fusi, A. et al. | 2015
- 40
-
Immune biomarkers of anti-EGFR monoclonal antibody therapyTrivedi, S. / Concha-Benavente, F. / Srivastava, R. M. / Jie, H. B. / Gibson, S. P. / Schmitt, N. C. / Ferris, R. L. et al. | 2015
- 47
-
Estimates of benefits and harms of prophylactic use of aspirin in the general populationCuzick, J. / Thorat, M. A. / Bosetti, C. / Brown, P. H. / Burn, J. / Cook, N. R. / Ford, L. G. / Jacobs, E. J. / Jankowski, J. A. / La Vecchia, C. et al. | 2015
- 58
-
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsTolcher, A. W. / Bendell, J. C. / Papadopoulos, K. P. / Burris, H. A. / Patnaik, A. / Jones, S. F. / Rasco, D. / Cox, D. S. / Durante, M. / Bellew, K. M. et al. | 2015
- 64
-
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataFavero, F. / Joshi, T. / Marquard, A. M. / Birkbak, N. J. / Krzystanek, M. / Li, Q. / Szallasi, Z. / Eklund, A. C. et al. | 2015
- 70
-
Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDERSun, Z. / Prat, A. / Cheang, M. C. / Gelber, R. D. / Perou, C. M. et al. | 2015
- 75
-
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapySheri, A. / Smith, I. E. / Johnston, S. R. / A'Hern, R. / Nerurkar, A. / Jones, R. L. / Hills, M. / Detre, S. / Pinder, S. E. / Symmans, W. F. et al. | 2015
- 81
-
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survivalTobin, N. P. / Harrell, J. C. / Lövrot, J. / Egyhazi Brage, S. / Frostvik Stolt, M. / Carlsson, L. / Einbeigi, Z. / Linderholm, B. / Loman, N. / Malmberg, M. et al. | 2015
- 89
-
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancerCao, K. I. / Lebas, N. / Gerber, S. / Levy, C. / Le Scodan, R. / Bourgier, C. / Pierga, J. Y. / Gobillion, A. / Savignoni, A. / Kirova, Y. M. et al. | 2015
- 95
-
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy†Lindner, J. L. / Loibl, S. / Denkert, C. / Ataseven, B. / Fasching, P. A. / Pfitzner, B. M. / Gerber, B. / Gade, S. / Darb-Esfahani, S. / Sinn, B. V. et al. | 2015
- 101
-
Obesity and the outcome of young breast cancer patients in the UK: the POSH studyCopson, E. R. / Cutress, R. I. / Maishman, T. / Eccles, B. K. / Gerty, S. / Stanton, L. / Altman, D. G. / Durcan, L. / Wong, C. / Simmonds, P. D. et al. | 2015
- 113
-
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†Krop, I. E. / Lin, N. U. / Blackwell, K. / Guardino, E. / Huober, J. / Lu, M. / Miles, D. / Samant, M. / Welslau, M. / Diéras, V. et al. | 2015
- 120
-
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancerTreilleux, I. / Arnedos, M. / Cropet, C. / Wang, Q. / Ferrero, J. M. / Abadie-Lacourtoisie, S. / Levy, C. / Legouffe, E. / Lortholary, A. / Pujade-Lauraine, E. et al. | 2015
- 126
-
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial†Klingbiel, D. / Saridaki, Z. / Roth, A. D. / Bosman, F. T. / Delorenzi, M. / Tejpar, S. et al. | 2015
- 132
-
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trialÉlez, E. / Kocáková, I. / Höhler, T. / Martens, U. M. / Bokemeyer, C. / Van Cutsem, E. / Melichar, B. / Smakal, M. / Csőszi, T. / Topuzov, E. et al. | 2015
- 141
-
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerYamada, Y. / Higuchi, K. / Nishikawa, K. / Gotoh, M. / Fuse, N. / Sugimoto, N. / Nishina, T. / Amagai, K. / Chin, K. / Niwa, Y. et al. | 2015
- 149
-
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyVan Cutsem, E. / Boni, C. / Tabernero, J. / Massuti, B. / Middleton, G. / Dane, F. / Reichardt, P. / Pimentel, F. L. / Cohn, A. / Follana, P. et al. | 2015
- 156
-
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growthKobayashi, Y. / Mitsudomi, T. / Sakao, Y. / Yatabe, Y. et al. | 2015
- 161
-
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencingSun, J. M. / Choi, Y. L. / Ji, J. H. / Ahn, J. S. / Kim, K. M. / Han, J. / Ahn, M. J. / Park, K. et al. | 2015
- 167
-
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study†Necchi, A. / Mariani, L. / Di Nicola, M. / Lo Vullo, S. / Nicolai, N. / Giannatempo, P. / Raggi, D. / Farè, E. / Magni, M. / Piva, L. et al. | 2015
- 173
-
Renal impairment and late toxicity in germ-cell cancer survivorsLauritsen, J. / Mortensen, M. S. / Kier, M. G. / Christensen, I. J. / Agerbaek, M. / Gupta, R. / Daugaard, G. et al. | 2015
- 179
-
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trialCella, D. / Ivanescu, C. / Holmstrom, S. / Bui, C. N. / Spalding, J. / Fizazi, K. et al. | 2015
- 185
-
Differences among young adults, adults and elderly chronic myeloid leukemia patientsCastagnetti, F. / Gugliotta, G. / Baccarani, M. / Breccia, M. / Specchia, G. / Levato, L. / Abruzzese, E. / Rossi, G. / Iurlo, A. / Martino, B. et al. | 2015
- 193
-
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomasBouabdallah, K. / Furst, S. / Asselineau, J. / Chevalier, P. / Tournilhac, O. / Ceballos, P. / Vigouroux, S. / Tabrizi, R. / Doussau, A. / Bouabdallah, R. et al. | 2015
- 198
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decadesDas, L. C. / Karrison, T. G. / Witt, M. E. / Muller, C. / Stenson, K. / Blair, E. A. / Cohen, E. E. / Seiwert, T. Y. / Haraf, D. J. / Vokes, E. E. et al. | 2015
- 205
-
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinomaChen, Y. P. / Wang, Z. X. / Chen, L. / Liu, X. / Tang, L. L. / Mao, Y. P. / Li, W. F. / Lin, A. H. / Sun, Y. / Ma, J. et al. | 2015
- 211
-
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agencyMaeda, H. / Kurokawa, T. et al. | 2015
- 217
-
Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?Gioulbasanis, I. / Martin, L. / Baracos, V. E. / Thézénas, S. / Koinis, F. / Senesse, P. et al. | 2015
- 221
-
Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†Wang, A. / Kubo, J. / Luo, J. / Desai, M. / Hedlin, H. / Henderson, M. / Chlebowski, R. / Tindle, H. / Chen, C. / Gomez, S. et al. | 2015
- 231
-
Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapyBylicki, O. / Gan, H. K. / Joly, F. / Maillet, D. / You, B. / Péron, J. et al. | 2015
- 238
-
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategiesIlie, M. I. / Bence, C. / Hofman, V. / Long-Mira, E. / Butori, C. / Bouhlel, L. / Lalvée, S. / Mouroux, J. / Poudenx, M. / Otto, J. et al. | 2015
- 245
-
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?Abali, H. / Yavuz, S. / Calıkusu, Z. / Seyrek, E. et al. | 2015
- 245
-
Reply to the Letter to the Editor ‘Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?’ by Abali et al.Sugihara, K. / Yoshida, M. / Ishiguro, M. et al. | 2015
- 246
-
A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenibRechsteiner, M. / Wild, P. / Kiessling, M. K. / Bohnert, A. / Zhong, Q. / Stahel, R. A. / Moch, H. / Curioni-Fontecedro, A. et al. | 2015
- 248
-
Pharmacokinetic interaction involving fenofibrate and everolimusMir, O. / Poinsignon, V. / Arnedos, M. / Delaloge, S. / Paci, A. et al. | 2015
- 249
-
Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al.Bertelli, G. / Quinton, A. E. / Lewis, P. D. / Ali, P. / Morgan, C. et al. | 2015
- 250
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.Schilling, B. / Sondermann, W. / Griewank, K. G. / Livingstone, E. / Zimmer, L. / Hillen, U. / Schadendorf, D. et al. | 2015
- 251
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Schilling et al.Davar, D. / Choi, T. / Kirkwood, J. M. et al. | 2015
- 252
-
Letter to the editor concerning ‘Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies’Hassan, W. A. / Bjerre, M. / Hjortebjerg, R. / Magnusson, N. E. / Ramshanker, N. / Frystyk, J. et al. | 2015
- 254
-
P–0271 Concurrent oral UFT and pelvic irradiation as neoadjuvant chemoradiation for operable rectal cancer: a phase II studyHelmy, S. / Abo-Zeid, A. A. / Gado, N. M. / Salman, M. I. / Bassyoni, M. M. / Abd Al Samee, A. / Salem, D. A. et al. | 2015
- 259
-
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Salgado, R. / Denkert, C. / Demaria, S. / Sirtaine, N. / Klauschen, F. / Pruneri, G. / Wienert, S. / Van den Eynden, G. / Baehner, F. L. / Penault-Llorca, F. et al. | 2015
- 272
-
Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysisSchmid, D. / Leitzmann, M. F. et al. | 2015
- 278
-
Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literatureCardenal, F. / Nadal, E. / Jové, M. / Faivre-Finn, C. et al. | 2015
- 288
-
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†Decoster, L. / Van Puyvelde, K. / Mohile, S. / Wedding, U. / Basso, U. / Colloca, G. / Rostoft, S. / Overcash, J. / Wildiers, H. / Steer, C. et al. | 2015
- 300
-
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paperCasali, P. G. / Bruzzi, P. / Bogaerts, J. / Blay, J. Y. et al. | 2015
- 307
-
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapyMontagna, E. / Bagnardi, V. / Viale, G. / Rotmensz, N. / Sporchia, A. / Cancello, G. / Balduzzi, A. / Galimberti, V. / Veronesi, P. / Luini, A. et al. | 2015
- 313
-
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12Gnant, M. / Mlineritsch, B. / Stoeger, H. / Luschin-Ebengreuth, G. / Knauer, M. / Moik, M. / Jakesz, R. / Seifert, M. / Taucher, S. / Bjelic-Radisic, V. et al. | 2015
- 320
-
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyJackisch, C. / Kim, S. B. / Semiglazov, V. / Melichar, B. / Pivot, X. / Hillenbach, C. / Stroyakovskiy, D. / Lum, B. L. / Elliott, R. / Weber, H. A. et al. | 2015
- 325
-
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyBonnefoi, H. / Jacot, W. / Saghatchian, M. / Moldovan, C. / Venat-Bouvet, L. / Zaman, K. / Matos, E. / Petit, T. / Bodmer, A. / Quenel-Tueux, N. et al. | 2015
- 332
-
Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancerSunakawa, Y. / Stremitzer, S. / Cao, S. / Zhang, W. / Yang, D. / Wakatsuki, T. / Ning, Y. / Yamauchi, S. / Stintzing, S. / Sebio, A. et al. | 2015
- 340
-
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialHebbar, M. / Chibaudel, B. / André, T. / Mineur, L. / Smith, D. / Louvet, C. / Dutel, J. L. / Ychou, M. / Legoux, J. L. / Mabro, M. et al. | 2015
- 368
-
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal eventsSmith, M. R. / Coleman, R. E. / Klotz, L. / Pittman, K. / Milecki, P. / Ng, S. / Chi, K. N. / Balakumaran, A. / Wei, R. / Wang, H. et al. | 2015
- 374
-
Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapyVidal, A. D. / Thalmann, G. N. / Karamitopoulou-Diamantis, E. / Fey, M. F. / Studer, U. E. et al. | 2015
- 407
-
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†Whelan, J. S. / Bielack, S. S. / Marina, N. / Smeland, S. / Jovic, G. / Hook, J. M. / Krailo, M. / Anninga, J. / Butterfass-Bahloul, T. / Böhling, T. et al. | 2015
- 415
-
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialMenzies, A. M. / Ashworth, M. T. / Swann, S. / Kefford, R. F. / Flaherty, K. / Weber, J. / Infante, J. R. / Kim, K. B. / Gonzalez, R. / Hamid, O. et al. | 2015
- 422
-
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trialsDoussau, A. / Thiébaut, R. / Geoerger, B. / Schöffski, P. / Floquet, A. / Le Deley, M. C. / Mathoulin-Pélissier, S. / Rizzo, E. / Fumoleau, P. / Le Tourneau, C. et al. | 2015
- 428
-
Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosisBarrera, L. / Montes-Servín, E. / Barrera, A. / Ramírez-Tirado, L. A. / Salinas-Parra, F. / Bañales-Méndez, J. L. / Sandoval-Ríos, M. / Arrieta, . et al. | 2015
- 436
-
T-DM1-related telangiectasias: a potential role in secondary bleeding eventsSibaud, V. / Vigarios, E. / Combemale, P. / Lamant, L. / Lacouture, M. E. / Lacaze, J. L. / Dalenc, F. / Delord, J. P. et al. | 2015
- 437
-
Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancerNeven, P. / Jongen, L. / Van Asten, K. / Berteloot, P. / Floris, G. / Wildiers, H. et al. | 2015
- 439
-
Can obesity be an advantage for febrile neutropenia?Alkan, A. / Bir, K. / Utkan, G. et al. | 2015
- 440
-
The obesity and cancer linkBifulco, M. et al. | 2015
- 441
-
The harms of low-dose aspirin prophylaxis are overstatedElwood, P. / Morgan, G. et al. | 2015
- 442
-
Reply to the letter to the editor ‘The harms of low-dose aspirin prophylaxis are overstated’ by P. Elwood and G. MorganThorat, M. A. / Cuzick, J. et al. | 2015
- 443
-
Albumin to globulin ratio, a predictor or a misleader?Alkan, A. / Köksoy, E. B. / Utkan, G. et al. | 2015
- 445
-
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsSoria, J. C. / DeBraud, F. / Bahleda, R. / Adamo, B. / Andre, F. / Dienstmann, R. / Delmonte, A. / Cereda, R. / Isaacson, J. / Litten, J. et al. | 2015
- 445
-
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features| 2015
- 447
-
The failure of figitumumab: the danger of taking shortcuts in drug developmentWest, H. et al. | 2015
- 448
-
Nit-Picking around second line in EGFRwt NSCLC: just an academic effortLandi, L. / Cappuzzo, F. et al. | 2015
- 463
-
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013Papamichael, D. / Audisio, R. A. / Glimelius, B. / de Gramont, A. / Glynne-Jones, R. / Haller, D. / K�hne, C. H. / Rostoft, S. / Lemmens, V. / Mitry, E. et al. | 2015
- 497
-
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerScagliotti, G. V. / Bondarenko, I. / Blackhall, F. / Barlesi, F. / Hsia, T. C. / Jassem, J. / Milanowski, J. / Popat, S. / Sanchez-Torres, J. M. / Novello, S. et al. | 2015
- 504
-
Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIAN2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapyLi, N. / Zeng, Z. F. / Wang, S. Y. / Ou, W. / Ye, X. / Li, J. / He, X. H. / Zhang, B. B. / Yang, H. / Sun, H. B. et al. | 2015
- 510
-
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patientsMostert, B. / Sieuwerts, A. M. / Kraan, J. / Bolt-de Vries, J. / van der Spoel, P. / van Galen, A. / Peeters, D. J. / Dirix, L. Y. / Seynaeve, C. M. / Jager, A. et al. | 2015
- 517
-
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancersLi, J. / Holm, J. / Bergh, J. / Eriksson, M. / Darabi, H. / Lindstr�m, L. S. / T�rnberg, S. / Hall, P. / Czene, K. et al. | 2015
- 523
-
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancerWang, C. / Zhang, J. / Wang, Y. / Ouyang, T. / Li, J. / Wang, T. / Fan, Z. / Fan, T. / Lin, B. / Xie, Y. et al. | 2015
- 529
-
Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) surveyBelkacemi, Y. / Kaidar-Person, O. / Poortmans, P. / Ozsahin, M. / Valli, M. C. / Russell, N. / Kunkler, I. / Hermans, J. / Kuten, A. / van Tienhoven, G. et al. | 2015
- 535
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancerSotelo, M. J. / Sastre, J. / Maestro, M. L. / Veganzones, S. / Vi�itez, J. M. / Alonso, V. / Gr�valos, C. / Escudero, P. / Vera, R. / Aranda, E. et al. | 2015
- 542
-
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studySantoro, A. / Gebbia, V. / Pressiani, T. / Testa, A. / Personeni, N. / Arrivas Bajardi, E. / Foa, P. / Buonadonna, A. / Bencardino, K. / Barone, C. et al. | 2015
- 548
-
EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?Hong, J. Y. / Yoon, D. H. / Suh, C. / Huh, J. / Do, I. G. / Sohn, I. / Jo, J. / Jung, S. H. / Hong, M. E. / Yoon, H. et al. | 2015
- 556
-
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerJimeno, A. / Shirai, K. / Choi, M. / Laskin, J. / Kochenderfer, M. / Spira, A. / Cline-Burkhardt, V. / Winquist, E. / Hausman, D. / Walker, L. et al. | 2015
- 561
-
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)Gr�nwald, V. / Keilholz, U. / Boehm, A. / Guntinas-Lichius, O. / Hennemann, B. / Schmoll, H. J. / Ivanyi, P. / Abbas, M. / Lehmann, U. / Koch, A. et al. | 2015
- 567
-
Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)Ferrari, A. / De Salvo, G. L. / Brennan, B. / van Noesel, M. M. / De Paoli, A. / Casanova, M. / Francotte, N. / Kelsey, A. / Alaggio, R. / Oberlin, O. et al. | 2015
- 573
-
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalUgurel, S. / Loquai, C. / K�hler, K. / Hassel, J. / Berking, C. / Zimmer, L. / Haubitz, I. / Satzger, I. / M�ller-Brenne, T. / Mikhaimer, N. C. et al. | 2015
- 582
-
Impact of centralization on aCGH-based genomic profiles for precision medicine in oncologyCommo, F. / Fert�, C. / Soria, J. C. / Friend, S. H. / Andr�, F. / Guinney, J. et al. | 2015
- 589
-
Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysisPetridou, E. T. / Sergentanis, T. N. / Perlepe, C. / Papathoma, P. / Tsilimidos, G. / Kontogeorgi, E. / Kourti, M. / Baka, M. / Moschovi, M. / Polychronopoulou, S. et al. | 2015
- 598
-
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II studySch�ffski, P. / Besse, B. / Gauler, T. / de Jonge, M. J. / Scambia, G. / Santoro, A. / Davite, C. / Jannuzzo, M. G. / Petroccione, A. / Delord, J. P. et al. | 2015
- 608
-
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphomaa long-term follow-up studyKasenda, B. / Schorb, E. / Fritsch, K. / Finke, J. / Illerhaus, G. et al. | 2015
- 613
-
Different adjuvant chemotherapy regimens in older breast cancer patients?Wildiers, H. / Brain, E. et al. | 2015
- 615
-
Postoperative surveillance in nonmetastatic colorectal cancer patients: yes, butCastells, A. et al. | 2015
- 617
-
Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit allCervantes, A. / Glynne-Jones, R. et al. | 2015
- 620
-
Contralateral biopsies in patients with testicular germ-cell tumournuisance or new sense?Dieckmann, K. P. et al. | 2015
- 622
-
Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomakers?Castro, E. / Lozano, R. / Olmos, D. et al. | 2015
- 624
-
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stageFindlay, J. M. / Middleton, M. R. / Tomlinson, I. et al. | 2015
- 644
-
Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysisPita-Fern�ndez, S. / Alhayek-A�, M. / Gonz�lez-Mart�n, C. / L�pez-Calvi�o, B. / Seoane-Pillado, T. / P�rtega-D�az, S. et al. | 2015
- 657
-
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomesGiannatempo, P. / Greco, T. / Mariani, L. / Nicolai, N. / Tana, S. / Far�, E. / Raggi, D. / Piva, L. / Catanzaro, M. / Biasoni, D. et al. | 2015
- 669
-
Designs of drug-combination phase I trials in oncology: a systematic review of the literatureRiviere, M. K. / Le Tourneau, C. / Paoletti, X. / Dubois, F. / Zohar, S. et al. | 2015
- 675
-
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialPerrone, F. / Nuzzo, F. / Di Rella, F. / Gravina, A. / Iodice, G. / Labonia, V. / Landi, G. / Pacilio, C. / Rossi, E. / De Laurentiis, M. et al. | 2015
- 682
-
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situCurigliano, G. / Disalvatore, D. / Esposito, A. / Pruneri, G. / Lazzeroni, M. / Guerrieri-Gonzaga, A. / Luini, A. / Orecchia, R. / Goldhirsch, A. / Rotmensz, N. et al. | 2015
- 688
-
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysisAapro, M. / Moebus, V. / Nitz, U. / O'Shaughnessy, J. / Pronzato, P. / Untch, M. / Tomita, D. / Bohac, C. / Leyland-Jones, B. et al. | 2015
- 696
-
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trialBreugom, A. J. / van Gijn, W. / Muller, E. W. / Berglund, . / van den Broek, C. B. / Fokstuen, T. / Gelderblom, H. / Kapiteijn, E. / Leer, J. W. / Marijnen, C. A. et al. | 2015
- 702
-
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trialGruenberger, T. / Bridgewater, J. / Chau, I. / Garc�a Alfonso, P. / Rivoire, M. / Mudan, S. / Lasserre, S. / Hermann, F. / Waterkamp, D. / Adam, R. et al. | 2015
- 709
-
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)Koeberle, D. / Betticher, D. C. / von Moos, R. / Dietrich, D. / Brauchli, P. / Baertschi, D. / Matter, K. / Winterhalder, R. / Borner, M. / Anchisi, S. et al. | 2015
- 715
-
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trialsHaller, D. G. / O'Connell, M. J. / Cartwright, T. H. / Twelves, C. J. / McKenna, E. F. / Sun, W. / Saif, M. W. / Lee, S. / Yothers, G. / Schmoll, H. J. et al. | 2015
- 724
-
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trialMasi, G. / Salvatore, L. / Boni, L. / Loupakis, F. / Cremolini, C. / Fornaro, L. / Schirripa, M. / Cupini, S. / Barbara, C. / Safina, V. et al. | 2015
- 731
-
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentMorelli, M. P. / Overman, M. J. / Dasari, A. / Kazmi, S. M. / Mazard, T. / Vilar, E. / Morris, V. K. / Lee, M. S. / Herron, D. / Eng, C. et al. | 2015
- 737
-
Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based studyKier, M. G. / Lauritsen, J. / Almstrup, K. / Mortensen, M. S. / Toft, B. G. / Rajpert-De Meyts, E. / Skakkebaek, N. E. / R�rth, M. / von der Maase, H. / Agerbaek, M. et al. | 2015
- 743
-
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsvan Soest, R. J. / Templeton, A. J. / Vera-Badillo, F. E. / Mercier, F. / Sonpavde, G. / Amir, E. / Tombal, B. / Rosenthal, M. / Eisenberger, M. A. / Tannock, I. F. et al. | 2015
- 750
-
Baseline neutrophillymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useLorente, D. / Mateo, J. / Templeton, A. J. / Zafeiriou, Z. / Bianchini, D. / Ferraldeschi, R. / Bahl, A. / Shen, L. / Su, Z. / Sartor, O. et al. | 2015
- 756
-
Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomesKote-Jarai, Z. / Mikropoulos, C. / Leongamornlert, D. A. / Dadaev, T. / Tymrakiewicz, M. / Saunders, E. J. / Jones, M. / Jugurnauth-Little, S. / Govindasami, K. / Guy, M. et al. | 2015
- 762
-
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancerLim, S. H. / Lee, J. Y. / Lee, M. Y. / Kim, H. S. / Lee, J. / Sun, J. M. / Ahn, J. S. / Um, S. W. / Kim, H. / Kim, B. S. et al. | 2015
- 768
-
Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ?4 cm in size: an SEERMedicare analysisMalhotra, J. / Mhango, G. / Gomez, J. E. / Smith, C. / Galsky, M. D. / Strauss, G. M. / Wisnivesky, J. P. et al. | 2015
- 774
-
Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaHorwitz, S. / Coiffier, B. / Foss, F. / Prince, H. M. / Sokol, L. / Greenwood, M. / Caballero, D. / Morschhauser, F. / Pinter-Brown, L. / Iyer, S. P. et al. | 2015
- 779
-
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?Malvezzi, M. / Bertuccio, P. / Rosso, T. / Rota, M. / Levi, F. / La Vecchia, C. / Negri, E. et al. | 2015
- 787
-
Low-dose aspirin use and the risk of ovarian cancer in DenmarkBaandrup, L. / Kjaer, S. K. / Olsen, J. H. / Dehlendorff, C. / Friis, S. et al. | 2015
- 793
-
Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer riskSamoli, E. / Lagiou, A. / Zourna, P. / Barbouni, A. / Georgila, C. / Tsikkinis, A. / Vassilarou, D. / Minaki, P. / Sfikas, C. / Spanos, E. et al. | 2015
- 798
-
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyDi Giacomo, A. M. / Ascierto, P. A. / Queirolo, P. / Pilla, L. / Ridolfi, R. / Santinami, M. / Testori, A. / Simeone, E. / Guidoboni, M. / Maurichi, A. et al. | 2015
- 804
-
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerBendell, J. / O'Reilly, E. M. / Middleton, M. R. / Chau, I. / Hochster, H. / Fielding, A. / Burke, W. / Burris, H. et al. | 2015
- 812
-
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinomaBellmunt, J. / Mullane, S. A. / Werner, L. / Fay, A. P. / Callea, M. / Leow, J. J. / Taplin, M. E. / Choueiri, T. K. / Hodi, F. S. / Freeman, G. J. et al. | 2015
- 818
-
Surrogate end points for overall survival. Festina lente (more haste, less speed)Braillon, A. et al. | 2015
- 818
-
Reply to the letter to the editor Surrogate end points for overall survival. Festina lente (more haste, less speed) by BraillonMaeda, H. / Kurokawa, T. et al. | 2015
- 819
-
Atypical femur fractures associated with use of bisphosphonates and denosumabFarooki, A. / Fornier, M. / Boland, P. et al. | 2015
- 820
-
Reply to the letter to the editor Albumin to globulin ratio, a predictor or a misleader? by Alkan et al.Suh, B. / Park, S. / Shin, D. W. et al. | 2015
- 821
-
Obesity and cancer: links with survival differ from those with incidenceRenehan, A. G. et al. | 2015
- 822
-
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset| 2015
- 827
-
Adapting the drivers to the road: a new strategy for cancer evolution?Touat, M. / Dhermain, F. / André, F. / Sanson, M. et al. | 2015
- 829
-
An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive againDittrich, C. / Negrouk, A. / Casali, P. G. et al. | 2015
- 833
-
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerOldenburg, J. / Aparicio, J. / Beyer, J. / Cohn-Cedermark, G. / Cullen, M. / Gilligan, T. / De Giorgi, U. / De Santis, M. / de Wit, R. / Fosså, S. D. et al. | 2015
- 838
-
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumorsSerpico, D. / Trama, A. / Haspinger, E. R. / Agustoni, F. / Botta, L. / Berardi, R. / Palmieri, G. / Zucali, P. / Gallucci, R. / Broggini, M. et al. | 2015
- 848
-
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysisLouie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 865
-
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Bellera, C. A. / Penel, N. / Ouali, M. / Bonvalot, S. / Casali, P. G. / Nielsen, O. S. / Delannes, M. / Litière, S. / Bonnetain, F. / Dabakuyo, T. S. et al. | 2015
- 873
-
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Gourgou-Bourgade, S. / Cameron, D. / Poortmans, P. / Asselain, B. / Azria, D. / Cardoso, F. / A'Hern, R. / Bliss, J. / Bogaerts, J. / Bonnefoi, H. et al. | 2015
- 880
-
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosomeFavero, F. / McGranahan, N. / Salm, M. / Birkbak, N. J. / Sanborn, J. Z. / Benz, S. C. / Becq, J. / Peden, J. F. / Kingsbury, Z. / Grocok, R. J. et al. | 2015
- 888
-
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Sugawara, S. / Oizumi, S. / Minato, K. / Harada, T. / Inoue, A. / Fujita, Y. / Maemondo, M. / Yoshizawa, H. / Ito, K. / Gemma, A. et al. | 2015
- 894
-
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†Blumenschein, G. R. / Smit, E. F. / Planchard, D. / Kim, D. W. / Cadranel, J. / De Pas, T. / Dunphy, F. / Udud, K. / Ahn, M. J. / Hanna, N. H. et al. | 2015
- 902
-
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosisJanssen-Heijnen, M. L. / van Erning, F. N. / De Ruysscher, D. K. / Coebergh, J. W. / Groen, H. J. et al. | 2015
- 908
-
Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†Pujol, J. L. / Lavole, A. / Quoix, E. / Molinier, O. / Souquet, P. J. / Barlesi, F. / Le Caer, H. / Moro-Sibilot, D. / Fournel, P. / Oster, J. P. et al. | 2015
- 914
-
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†Monk, B. J. / Ghatage, P. / Parekh, T. / Henitz, E. / Knoblauch, R. / Matos-Pita, A. S. / Nieto, A. / Park, Y. C. / Cheng, P. S. / Li, W. et al. | 2015
- 921
-
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†Fuchs, C. S. / Azevedo, S. / Okusaka, T. / Van Laethem, J. L. / Lipton, L. R. / Riess, H. / Szczylik, C. / Moore, M. J. / Peeters, M. / Bodoky, G. et al. | 2015
- 928
-
Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapyvan Gijn, W. / van Stiphout, R. G. / van de Velde, C. J. / Valentini, V. / Lammering, G. / Gambacorta, M. A. / Påhlman, L. / Bujko, K. / Lambin, P. et al. | 2015
- 935
-
The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYCTakahashi, Y. / Sheridan, P. / Niida, A. / Sawada, G. / Uchi, R. / Mizuno, H. / Kurashige, J. / Sugimachi, K. / Sasaki, S. / Shimada, Y. et al. | 2015
- 943
-
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerChen, J. S. / Hsu, C. / Chiang, N. J. / Tsai, C. S. / Tsou, H. H. / Huang, S. F. / Bai, L. Y. / Chang, I. C. / Shiah, H. S. / Ho, C. L. et al. | 2015
- 950
-
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†Renfro, L. A. / Grothey, A. / Kerr, D. / Haller, D. G. / André, T. / Van Cutsem, E. / Saltz, L. / Labianca, R. / Loprinzi, C. L. / Alberts, S. R. et al. | 2015
- 958
-
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaBarta, S. K. / Samuel, M. S. / Xue, X. / Wang, D. / Lee, J. Y. / Mounier, N. / Ribera, J. M. / Spina, M. / Tirelli, U. / Weiss, R. et al. | 2015
- 966
-
Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)Chihara, D. / Asano, N. / Ohmachi, K. / Nishikori, M. / Okamoto, M. / Sawa, M. / Sakai, R. / Okoshi, Y. / Tsukamoto, N. / Yakushijin, Y. et al. | 2015
- 973
-
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200†Chu, Q. S. / Nielsen, T. O. / Alcindor, T. / Gupta, A. / Endo, M. / Goytain, A. / Xu, H. / Verma, S. / Tozer, R. / Knowling, M. et al. | 2015
- 981
-
Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort studyMattsson, T. O. / Holm, B. / Michelsen, H. / Knudsen, J. L. / Brixen, K. / Herrstedt, J. et al. | 2015
- 987
-
Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastasesde Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 992
-
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions†van Leeuwen, R. W. / Jansman, F. G. / van den Bemt, P. M. / de Man, F. / Piran, F. / Vincenten, I. / Jager, A. / Rijneveld, A. W. / Brugma, J. D. / Mathijssen, R. H. et al. | 2015
- 998
-
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignanciesWong, A. L. / Soo, R. A. / Tan, D. S. / Lee, S. C. / Lim, J. S. / Marban, P. C. / Kong, L. R. / Lee, Y. J. / Wang, L. Z. / Thuya, W. L. et al. | 2015
- 1005
-
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phaseIsambert, N. / Delord, J. P. / Soria, J. C. / Hollebecque, A. / Gomez-Roca, C. / Purcea, D. / Rouits, E. / Belli, R. / Fumoleau, P. et al. | 2015
- 1012
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationFu, S. / Hou, M. M. / Naing, A. / Janku, F. / Hess, K. / Zinner, R. / Subbiah, V. / Hong, D. / Wheler, J. / Piha-Paul, S. et al. | 2015
- 1019
-
Molecular phenotypes of DCIS predict overall and invasive recurrence†Williams, K. E. / Barnes, N. L. / Cramer, A. / Johnson, R. / Cheema, K. / Morris, J. / Howe, M. / Bundred, N. J. et al. | 2015
- 1025
-
Long-term effects of inhaled budesonide on screening-detected lung nodulesVeronesi, G. / Lazzeroni, M. / Szabo, E. / Brown, P. H. / DeCensi, A. / Guerrieri-Gonzaga, A. / Bellomi, M. / Radice, D. / Grimaldi, M. C. / Spaggiari, L. et al. | 2015
- 1031
-
Reply to the letter to the editor ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’ by Louie et al.Louie, K. S. / Seigneurin, A. / Cathcart, P. / Sasieni, P. et al. | 2015
- 1031
-
Letter to the editor concerning ‘Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis’Carlsson, S. / Assel, M. / Vickers, A. et al. | 2015
- 1032
-
Choosing a better end point for trials of bone-protective agentsLeibowitz-Amit, R. / Khoja, L. / Tannock, I. F. / Joshua, A. M. et al. | 2015
- 1033
-
Letter to the editor concerning ‘Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA’Foglietta, J. / Metro, G. / Crinò, L. / Gori, S. et al. | 2015
- 1034
-
How can I validate a nomogram? Show me the modelCollins, G. S. et al. | 2015
- 1035
-
Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancerRossi, G. / Baldi, L. / Barbieri, F. / Bertolini, F. / Tiseo, M. et al. | 2015
- 1036
-
Recent developments in the implementation of novel designs for early-phase combination studiesWages, N. A. / Conaway, M. R. / Slingluff, C. L. / Williams, M. E. / Portell, C. A. / Hwu, P. / Petroni, G. R. et al. | 2015
- 1038
-
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma| 2015
- 1041
-
Prioritizing precision medicine for prostate cancerAttard, G. / Beltran, H. et al. | 2015
- 1043
-
Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteriaRussell, N. S. / Kunkler, I. H. / van Tienhoven, G. et al. | 2015
- 1045
-
Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?Gallamini, A. / Kostakoglu, L. et al. | 2015
- 1048
-
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?Woolf, D. K. / Padhani, A. R. / Makris, A. et al. | 2015
- 1058
-
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryMorrison, V. A. / Hamlin, P. / Soubeyran, P. / Stauder, R. / Wadhwa, P. / Aapro, M. / Lichtman, S. M. et al. | 2015
- 1069
-
Genetic lesions in diffuse large B-cell lymphomasTestoni, M. / Zucca, E. / Young, K. H. / Bertoni, F. et al. | 2015
- 1081
-
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewJordan, K. / Jahn, F. / Aapro, M. et al. | 2015
- 1091
-
The prevalence and outcomes of frailty in older cancer patients: a systematic reviewHandforth, C. / Clegg, A. / Young, C. / Simpkins, S. / Seymour, M. T. / Selby, P. J. / Young, J. et al. | 2015
- 1101
-
Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studiesKeum, N. / Lee, D. H. / Kim, R. / Greenwood, D. C. / Giovannucci, E. L. et al. | 2015
- 1110
-
Integrative molecular profiling of routine clinical prostate cancer specimensGrasso, C. S. / Cani, A. K. / Hovelson, D. H. / Quist, M. J. / Douville, N. J. / Yadati, V. / Amin, A. M. / Nelson, P. S. / Betz, B. L. / Liu, C. J. et al. | 2015
- 1118
-
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaDavis, I. D. / Long, A. / Yip, S. / Espinoza, D. / Thompson, J. F. / Kichenadasse, G. / Harrison, M. / Lowenthal, R. M. / Pavlakis, N. / Azad, A. et al. | 2015
- 1123
-
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†Ravaud, A. / Oudard, S. / De Fromont, M. / Chevreau, C. / Gravis, G. / Zanetta, S. / Theodore, C. / Jimenez, M. / Sevin, E. / Laguerre, B. et al. | 2015
- 1128
-
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinomaIzzedine, H. / Derosa, L. / Le Teuff, G. / Albiges, L. / Escudier, B. et al. | 2015
- 1134
-
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analysesMitchell, P. / Thatcher, N. / Socinski, M. A. / Wasilewska-Tesluk, E. / Horwood, K. / Szczesna, A. / Martín, C. / Ragulin, Y. / Zukin, M. / Helwig, C. et al. | 2015
- 1142
-
A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancerLee, S. Y. / Choi, J. E. / Jeon, H. S. / Hong, M. J. / Choi, Y. Y. / Kang, H. G. / Yoo, S. S. / Lee, E. B. / Jeong, J. Y. / Lee, W. K. et al. | 2015
- 1149
-
No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based studyNordenskjöld, A. E. / Fohlin, H. / Albertsson, P. / Arnesson, L. G. / Chamalidou, C. / Einbeigi, Z. / Holmberg, E. / Nordenskjöld, B. / Karlsson, P. et al. | 2015
- 1155
-
Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapseHartkopf, A. D. / Wallwiener, M. / Fehm, T. N. / Hahn, M. / Walter, C. B. / Gruber, I. / Brucker, S. Y. / Taran, F. A. et al. | 2015
- 1161
-
Survival in stage I–III breast cancer patients by surgical treatment in a publicly funded health care systemFisher, S. / Gao, H. / Yasui, Y. / Dabbs, K. / Winget, M. et al. | 2015
- 1170
-
Phase II study of interim PET–CT-guided response-adapted therapy in advanced Hodgkin's lymphomaGanesan, P. / Rajendranath, R. / Kannan, K. / Radhakrishnan, V. / Ganesan, T. S. / Udupa, K. / Lakshmipathy, K. M. / Mahajan, V. / Sundersingh, S. / Rajaraman, S. et al. | 2015
- 1175
-
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesCheah, C. Y. / Chihara, D. / Romaguera, J. E. / Fowler, N. H. / Seymour, J. F. / Hagemeister, F. B. / Champlin, R. E. / Wang, M. L. et al. | 2015
- 1180
-
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemiaKorfi, K. / Mandal, A. / Furney, S. J. / Wiseman, D. / Somervaille, T. C. / Marais, R. et al. | 2015
- 1188
-
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestCremolini, C. / Loupakis, F. / Antoniotti, C. / Lonardi, S. / Masi, G. / Salvatore, L. / Cortesi, E. / Tomasello, G. / Spadi, R. / Zaniboni, A. et al. | 2015
- 1194
-
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerDeplanque, G. / Demarchi, M. / Hebbar, M. / Flynn, P. / Melichar, B. / Atkins, J. / Nowara, E. / Moyé, L. / Piquemal, D. / Ritter, D. et al. | 2015
- 1201
-
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trialPassardi, A. / Nanni, O. / Tassinari, D. / Turci, D. / Cavanna, L. / Fontana, A. / Ruscelli, S. / Mucciarini, C. / Lorusso, V. / Ragazzini, A. et al. | 2015
- 1208
-
Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial†Delbaldo, C. / Ychou, M. / Zawadi, A. / Douillard, J. Y. / André, T. / Guerin-Meyer, V. / Rougier, P. / Dupuis, O. / Faroux, R. / Jouhaud, A. et al. | 2015
- 1216
-
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencingChung, C. H. / Guthrie, V. B. / Masica, D. L. / Tokheim, C. / Kang, H. / Richmon, J. / Agrawal, N. / Fakhry, C. / Quon, H. / Subramaniam, R. M. et al. | 2015
- 1223
-
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancerDeutsch, E. / Le Péchoux, C. / Faivre, L. / Rivera, S. / Tao, Y. / Pignon, J. P. / Angokai, M. / Bahleda, R. / Deandreis, D. / Angevin, E. et al. | 2015
- 1230
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumorsChiorean, E. G. / Hurwitz, H. I. / Cohen, R. B. / Schwartz, J. D. / Dalal, R. P. / Fox, F. E. / Gao, L. / Sweeney, C. J. et al. | 2015
- 1238
-
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patientsHecht, M. / Zimmer, L. / Loquai, C. / Weishaupt, C. / Gutzmer, R. / Schuster, B. / Gleisner, S. / Schulze, B. / Goldinger, S. M. / Berking, C. et al. | 2015
- 1244
-
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)Al-Batran, S. E. / Hozaeel, W. / Tauchert, F. K. / Hofheinz, R. D. / Hinke, A. / Windemuth-Kieselbach, C. / Hübner, A. / Burmester, M. / Koenigsmann, M. / Wiegand, J. et al. | 2015
- 1248
-
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind studyRoila, F. / Ruggeri, B. / Ballatori, E. / Fatigoni, S. / Caserta, C. / Licitra, L. / Mirabile, A. / Ionta, M. T. / Massidda, B. / Cavanna, L. et al. | 2015
- 1254
-
Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trialFontein, D. B. / Klinten Grand, M. / Nortier, J. W. / Seynaeve, C. / Meershoek-Klein Kranenbarg, E. / Dirix, L. Y. / van de Velde, C. J. / Putter, H. et al. | 2015
- 1263
-
Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based dataCapocaccia, R. / Gatta, G. / Dal Maso, L. et al. | 2015
- 1269
-
Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al.Pivot, X. / Machackova, Z. et al. | 2015
- 1269
-
Patients' preference and informed consentPumo, V. / Di Mari, A. / Rametta Giuliano, S. / Bordonaro, S. / Lanteri, E. / Tralongo, P. et al. | 2015
- 1270
-
Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the makingPassaro, A. / Barberis, M. / Catania, C. / Pessina, S. / de Marinis, F. et al. | 2015
- 1272
-
Reply to the letter to the editor ‘Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?’ by Conde-Estévez et al.van Leeuwen, R. W. / Mathijssen, R. H. / Jansman, F. G. / van Gelder, T. et al. | 2015
- 1272
-
Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?Conde-Estévez, D. / Echeverría-Esnal, D. / Tusquets, I. / Albanell, J. et al. | 2015
- 1275
-
De-escalation attempts for adjuvant trastuzumab: longer beats shorterCurigliano, G. / Goldhirsch, A. et al. | 2015
- 1277
-
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?Mir, O. / Dumont, S. / Armand, J. P. et al. | 2015
- 1279
-
‘Industry corner: perspectives and controversies’: a new series in Annals of OncologyDhingra, K. et al. | 2015
- 1280
-
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaborationBossuyt, V. / Provenzano, E. / Symmans, W. F. / Boughey, J. C. / Coles, C. / Curigliano, G. / Dixon, J. M. / Esserman, L. J. / Fastner, G. / Kuehn, T. et al. | 2015
- 1291
-
Genetics of breast cancer: a topic in evolutionShiovitz, S. / Korde, L. A. et al. | 2015
- 1300
-
Alternate sunitinib schedules in patients with metastatic renal cell carcinomaKalra, S. / Rini, B. I. / Jonasch, E. et al. | 2015
- 1305
-
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysisKasenda, B. / Ferreri, A. J. / Marturano, E. / Forst, D. / Bromberg, J. / Ghesquieres, H. / Ferlay, C. / Blay, J. Y. / Hoang-Xuan, K. / Pulczynski, E. J. et al. | 2015
- 1314
-
The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosisSexton-Oates, A. / MacGregor, D. / Dodgshun, A. / Saffery, R. et al. | 2015
- 1325
-
Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic reviewStairmand, J. / Signal, L. / Sarfati, D. / Jackson, C. / Batten, L. / Holdaway, M. / Cunningham, C. et al. | 2015
- 1333
-
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)Mavroudis, D. / Saloustros, E. / Malamos, N. / Kakolyris, S. / Boukovinas, I. / Papakotoulas, P. / Kentepozidis, N. / Ziras, N. / Georgoulias, V. et al. | 2015
- 1340
-
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trialJamal-Hanjani, M. / A'Hern, R. / Birkbak, N. J. / Gorman, P. / Grönroos, E. / Ngang, S. / Nicola, P. / Rahman, L. / Thanopoulou, E. / Kelly, G. et al. | 2015
- 1346
-
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancerMoulder, S. / Helgason, T. / Janku, F. / Wheler, J. / Moroney, J. / Booser, D. / Albarracin, C. / Morrow, P. K. / Atkins, J. / Koenig, K. et al. | 2015
- 1353
-
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patientsTrédan, O. / Ménétrier-Caux, C. / Ray-Coquard, I. / Garin, G. / Cropet, C. / Verronèse, E. / Bachelot, T. / Rebattu, P. / Heudel, P. E. / Cassier, P. et al. | 2015
- 1363
-
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective studyBeltrame, L. / Di Marino, M. / Fruscio, R. / Calura, E. / Chapman, B. / Clivio, L. / Sina, F. / Mele, C. / Iatropoulos, P. / Grassi, T. et al. | 2015
- 1372
-
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinomaRini, B. I. / Melichar, B. / Fishman, M. N. / Oya, M. / Pithavala, Y. K. / Chen, Y. / Bair, A. H. / Grünwald, V. et al. | 2015
- 1378
-
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaRavaud, A. / Barrios, C. H. / Alekseev, B. / Tay, M. H. / Agarwala, S. S. / Yalcin, S. / Lin, C. C. / Roman, L. / Shkolnik, M. / Anak, O. et al. | 2015
- 1385
-
Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent linesBodnar, L. / Stec, R. / Cierniak, S. / Synowiec, A. / Wcisło, G. / Jesiotr, M. / Koktysz, R. / Kozłowski, W. / Szczylik, C. et al. | 2015
- 1390
-
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?Mahal, B. A. / Chen, M. H. / Bennett, C. L. / Kattan, M. W. / Sartor, O. / Stein, K. / D'Amico, A. V. / Nguyen, P. L. et al. | 2015
- 1396
-
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasionLago-Hernandez, C. A. / Feldman, H. / O'Donnell, E. / Mahal, B. A. / Perez, V. / Howard, S. / Rosenthal, M. / Cheng, S. C. / Nguyen, P. L. / Beard, C. et al. | 2015
- 1401
-
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trialKubota, K. / Sakai, H. / Katakami, N. / Nishio, M. / Inoue, A. / Okamoto, H. / Isobe, H. / Kunitoh, H. / Takiguchi, Y. / Kobayashi, K. et al. | 2015
- 1408
-
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerPailler, E. / Auger, N. / Lindsay, C. R. / Vielh, P. / Islas-Morris-Hernandez, A. / Borget, I. / Ngo-Camus, M. / Planchard, D. / Soria, J. C. / Besse, B. et al. | 2015
- 1415
-
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerâ€Lim, C. / Tsao, M. S. / Le, L. W. / Shepherd, F. A. / Feld, R. / Burkes, R. L. / Liu, G. / Kamel-Reid, S. / Hwang, D. / Tanguay, J. et al. | 2015
- 1421
-
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsKris, M. G. / Camidge, D. R. / Giaccone, G. / Hida, T. / Li, B. T. / O'Connell, J. / Taylor, I. / Zhang, H. / Arcila, M. E. / Goldberg, Z. et al. | 2015
- 1427
-
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE studyâ€Iwamoto, S. / Takahashi, T. / Tamagawa, H. / Nakamura, M. / Munemoto, Y. / Kato, T. / Hata, T. / Denda, T. / Morita, Y. / Inukai, M. et al. | 2015
- 1434
-
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)â€Thiel, A. / Schetelig, J. / Pönisch, W. / Schäfer-Eckart, K. / Aulitzky, W. / Peter, N. / Schulze, A. / Maschmeyer, G. / Neugebauer, S. / Herbst, R. et al. | 2015
- 1440
-
Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialistsHui, D. / Bansal, S. / Park, M. / Reddy, A. / Cortes, J. / Fossella, F. / Bruera, E. et al. | 2015
- 1446
-
Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort studyâ€Cheung, Y. T. / Ng, T. / Shwe, M. / Ho, H. K. / Foo, K. M. / Cham, M. T. / Lee, J. A. / Fan, G. / Tan, Y. P. / Yong, W. S. et al. | 2015
- 1452
-
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapyLyman, G. H. / Reiner, M. / Morrow, P. K. / Crawford, J. et al. | 2015
- 1459
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelChugh, R. / Griffith, K. A. / Davis, E. J. / Thomas, D. G. / Zavala, J. D. / Metko, G. / Brockstein, B. / Undevia, S. D. / Stadler, W. M. / Schuetze, S. M. et al. | 2015
- 1465
-
Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II studyToulmonde, M. / Le Cesne, A. / Piperno-Neumann, S. / Penel, N. / Chevreau, C. / Duffaud, F. / Bellera, C. / Italiano, A. et al. | 2015
- 1470
-
Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and toleranceâ€Funck-Brentano, E. / Alvarez, J. C. / Longvert, C. / Abe, E. / Beauchet, A. / Funck-Brentano, C. / Saiag, P. et al. | 2015
- 1476
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinomaMassarelli, E. / Lin, H. / Ginsberg, L. E. / Tran, H. T. / Lee, J. J. / Canales, J. R. / Williams, M. D. / Blumenschein, G. R. / Lu, C. / Heymach, J. V. et al. | 2015
- 1481
-
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumorsâ€Rosenthal, E. L. / Chung, T. K. / Parker, W. B. / Allan, P. W. / Clemons, L. / Lowman, D. / Hong, J. / Hunt, F. R. / Richman, J. / Conry, R. M. et al. | 2015
- 1488
-
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytesAli, H. R. / Glont, S. E. / Blows, F. M. / Provenzano, E. / Dawson, S. J. / Liu, B. / Hiller, L. / Dunn, J. / Poole, C. J. / Bowden, S. et al. | 2015
- 1494
-
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) statusNuciforo, P. G. / Aura, C. / Holmes, E. / Prudkin, L. / Jimenez, J. / Martinez, P. / Ameels, H. / de la Peña, L. / Ellis, C. / Eidtmann, H. et al. | 2015
- 1500
-
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon modelJovelet, C. / Seck, A. / Mir, O. / Simasotchi, C. / Broutin, S. / Goffinet, F. / Bidart, J. M. / Paci, A. / Gil, S. et al. | 2015
- 1504
-
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsStewart, A. / Thavasu, P. / de Bono, J. S. / Banerji, U. et al. | 2015
- 1511
-
Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patientsFouad, T. M. / de Azambuja, E. / Azim, H. A. et al. | 2015
- 1511
-
Sunitinib 2 weeks on, 1 off: strengths and weaknessesIacovelli, R. / Verri, E. / Cossu Rocca, M. / Aurilio, G. / Cullurà , D. / Nolé, F. et al. | 2015
- 1512
-
Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW studyBracarda, S. et al. | 2015
- 1513
-
Agenda science: turning nothing into something: a response to the editorial by Oldenburg et al. and its featured article by Vidal et al.Kollmannsberger, C. / Nichols, C. et al. | 2015
- 1514
-
ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancerUguen, A. / Talagas, M. / Andrieu-Key, S. / Costa, S. / Quintin-Roué, I. / De Braekeleer, M. / Marcorelles, P. et al. | 2015
- 1515
-
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinibSpraggs, C. F. / Parham, L. R. / Song, K. / Briley, L. P. / Johnson, T. / Russo, M. / Tada, H. / du Bois, A. / Xu, C. F. et al. | 2015
- 1518
-
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyDieci, M. V. / Criscitiello, C. / Goubar, A. / Viale, G. / Conte, P. / Guarneri, V. / Ficarra, G. / Mathieu, M. C. / Delaloge, S. / Curigliano, G. et al. | 2015
- 1805
-
Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?Sprenger, C. / Uo, T. / Plymate, S. et al. | 2015
- 1808
-
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsPaoletti, X. / Ezzalfani, M. / Le Tourneau, C. et al. | 2015
- 1813
-
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Apetoh, L. / Ladoire, S. / Coukos, G. / Ghiringhelli, F. et al. | 2015
- 1824
-
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors†Chen, T. W. / Razak, A. R. / Bedard, P. L. / Siu, L. L. / Hansen, A. R. et al. | 2015
- 1830
-
A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicineHeuckmann, J. M. / Thomas, R. K. et al. | 2015
- 1838
-
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†Lee, R. T. / Ramchandran, K. / Sanft, T. / Von Roenn, J. et al. | 2015
- 1846
-
Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factorsHowell, D. / Molloy, S. / Wilkinson, K. / Green, E. / Orchard, K. / Wang, K. / Liberty, J. et al. | 2015
- 1859
-
Serial blood-based analysis of AR-V7 in men with advanced prostate cancerNakazawa, M. / Lu, C. / Chen, Y. / Paller, C. J. / Carducci, M. A. / Eisenberger, M. A. / Luo, J. / Antonarakis, E. S. et al. | 2015
- 1865
-
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experienceChau, C. / Cathomas, R. / Wheater, M. / Klingbiel, D. / Fehr, M. / Bennett, J. / Markham, H. / Lee, C. / Crabb, S. J. / Geldart, T. et al. | 2015
- 1871
-
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinomaNaito, S. / Sakai, H. / Hashine, K. / Tomita, Y. / Shinohara, N. / Fujisawa, M. / Eto, M. / Ozono, S. / Akaza, H. et al. | 2015
- 1877
-
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Zhou, C. / Wu, Y. L. / Chen, G. / Feng, J. / Liu, X. Q. / Wang, C. / Zhang, S. / Wang, J. / Zhou, S. / Ren, S. et al. | 2015
- 1883
-
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†Wu, Y. L. / Zhou, C. / Liam, C. K. / Wu, G. / Liu, X. / Zhong, Z. / Lu, S. / Cheng, Y. / Han, B. / Chen, L. et al. | 2015
- 1890
-
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES†Speirs, V. / Viale, G. / Mousa, K. / Palmieri, C. / Reed, S. N. / Nicholas, H. / Cheang, M. / Jassem, J. / Lønning, P. E. / Kalaitzaki, E. et al. | 2015
- 1898
-
Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast†Lo, A. C. / Truong, P. T. / Wai, E. S. / Nichol, A. / Weir, L. / Speers, C. / Hayes, M. M. / Baliski, C. / Tyldesley, S. et al. | 2015
- 1904
-
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerDiéras, V. / Campone, M. / Yardley, D. A. / Romieu, G. / Valero, V. / Isakoff, S. J. / Koeppen, H. / Wilson, T. R. / Xiao, Y. / Shames, D. S. et al. | 2015
- 1910
-
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studiesGrenader, T. / Nash, S. / Plotkin, Y. / Furuse, J. / Mizuno, N. / Okusaka, T. / Wasan, H. / Valle, J. / Bridgewater, J. et al. | 2015
- 1916
-
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)Tanabe, K. / Fujii, M. / Nishikawa, K. / Kunisaki, C. / Tsuji, A. / Matsuhashi, N. / Takagane, A. / Ohno, T. / Kawase, T. / Kochi, M. et al. | 2015
- 1923
-
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer†O'Neil, B. H. / Scott, A. J. / Ma, W. W. / Cohen, S. J. / Aisner, D. L. / Menter, A. R. / Tejani, M. A. / Cho, J. K. / Granfortuna, J. / Coveler, L. et al. | 2015
- 1930
-
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogramGroot Koerkamp, B. / Wiggers, J. K. / Gonen, M. / Doussot, A. / Allen, P. J. / Besselink, M. G. / Blumgart, L. H. / Busch, O. R. / D'Angelica, M. I. / DeMatteo, R. P. et al. | 2015
- 1936
-
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trialSclafani, F. / Chau, I. / Cunningham, D. / Peckitt, C. / Lampis, A. / Hahne, J. C. / Braconi, C. / Tabernero, J. / Glimelius, B. / Cervantes, A. et al. | 2015
- 1941
-
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC studyGuigay, J. / Fayette, J. / Dillies, A. F. / Sire, C. / Kerger, J. N. / Tennevet, I. / Machiels, J. P. / Zanetta, S. / Pointreau, Y. / Bozec Le Moal, L. et al. | 2015
- 1948
-
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyBlackwell, K. / Semiglazov, V. / Krasnozhon, D. / Davidenko, I. / Nelyubina, L. / Nakov, R. / Stiegler, G. / Singh, P. / Schwebig, A. / Kramer, S. et al. | 2015
- 1953
-
Indicators of integration of oncology and palliative care programs: an international consensusHui, D. / Bansal, S. / Strasser, F. / Morita, T. / Caraceni, A. / Davis, M. / Cherny, N. / Kaasa, S. / Currow, D. / Abernethy, A. et al. | 2015
- 1960
-
High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancerEngelen, M. P. / Safar, A. M. / Bartter, T. / Koeman, F. / Deutz, N. E. et al. | 2015
- 1966
-
Planning and reporting of quality-of-life outcomes in cancer trialsSchandelmaier, S. / Conen, K. / von Elm, E. / You, J. J. / Blümle, A. / Tomonaga, Y. / Amstutz, A. / Briel, M. / Kasenda, B. et al. | 2015
- 1974
-
Association between information provision and decisional conflict in cancer patientsSim, J. A. / Shin, J. S. / Park, S. M. / Chang, Y. J. / Shin, A. / Noh, D. Y. / Han, W. / Yang, H. K. / Lee, H. J. / Kim, Y. W. et al. | 2015
- 1980
-
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600Massi, D. / Brusa, D. / Merelli, B. / Falcone, C. / Xue, G. / Carobbio, A. / Nassini, R. / Baroni, G. / Tamborini, E. / Cattaneo, L. et al. | 2015
- 1987
-
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)†Grande, E. / Capdevila, J. / Castellano, D. / Teulé, A. / Durán, I. / Fuster, J. / Sevilla, I. / Escudero, P. / Sastre, J. / García-Donas, J. et al. | 2015
- 1994
-
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancerBarault, L. / Amatu, A. / Bleeker, F. E. / Moutinho, C. / Falcomatà, C. / Fiano, V. / Cassingena, A. / Siravegna, G. / Milione, M. / Cassoni, P. et al. | 2015
- 2000
-
Cross-over—it's a feature, not a bugEngelsberg, A. et al. | 2015
- 2003
-
Flaws in the trial design of IFCT-0802Gyawali, B. / Shimokata, T. / Honda, K. / Ando, Y. et al. | 2015
- 2003
-
Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?Schrijvers, D. L. et al. | 2015
- 2007
-
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET…Scagliotti, G. V. / Di Maio, M. et al. | 2015
- 2010
-
Academically led clinical trials: challenges and opportunitiesTurajlic, S. / Larkin, J. / Swanton, C. et al. | 2015
- 2012
-
Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteriaHeller, G. et al. | 2015
- 2017
-
Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and managementMcLellan, B. / Ciardiello, F. / Lacouture, M. E. / Segaert, S. / Van Cutsem, E. et al. | 2015
- 2026
-
The new therapeutical scenario of Hodgkin lymphomaStathis, A. / Younes, A. et al. | 2015
- 2034
-
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatmentsLedermann, J. A. / Canevari, S. / Thigpen, T. et al. | 2015
- 2044
-
Treatment of mCRPC in the AR-axis-targeted therapy-resistant stateChi, K. / Hotte, S. J. / Joshua, A. M. / North, S. / Wyatt, A. W. / Collins, L. L. / Saad, F. et al. | 2015
- 2057
-
BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significanceEccles, D. M. / Mitchell, G. / Monteiro, A. N. / Schmutzler, R. / Couch, F. J. / Spurdle, A. B. / Gómez-García, E. B. et al. | 2015
- 2066
-
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)Yoshioka, H. / Azuma, K. / Yamamoto, N. / Takahashi, T. / Nishio, M. / Katakami, N. / Ahn, M. J. / Hirashima, T. / Maemondo, M. / Kim, S. W. et al. | 2015
- 2073
-
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patientsPlanchard, D. / Loriot, Y. / André, F. / Gobert, A. / Auger, N. / Lacroix, L. / Soria, J. C. et al. | 2015
- 2079
-
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialRulli, E. / Marabese, M. / Torri, V. / Farina, G. / Veronese, S. / Bettini, A. / Longo, F. / Moscetti, L. / Ganzinelli, M. / Lauricella, C. et al. | 2015
- 2085
-
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patientsVan Cutsem, E. / Prenen, H. / D'Haens, G. / Bennouna, J. / Carrato, A. / Ducreux, M. / Bouché, O. / Sobrero, A. / Latini, L. / Staines, H. et al. | 2015
- 2092
-
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisCremolini, C. / Di Bartolomeo, M. / Amatu, A. / Antoniotti, C. / Moretto, R. / Berenato, R. / Perrone, F. / Tamborini, E. / Aprile, G. / Lonardi, S. et al. | 2015
- 2097
-
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)Ryu, M. H. / Baba, E. / Lee, K. H. / Park, Y. I. / Boku, N. / Hyodo, I. / Nam, B. H. / Esaki, T. / Yoo, C. / Ryoo, B. Y. et al. | 2015
- 2102
-
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancerJiang, D. M. / Raissouni, S. / Mercer, J. / Kumar, A. / Goodwin, R. / Heng, D. Y. / Tang, P. A. / Doll, C. / MacLean, A. / Powell, E. et al. | 2015
- 2107
-
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisBracarda, S. / Iacovelli, R. / Boni, L. / Rizzo, M. / Derosa, L. / Rossi, M. / Galli, L. / Procopio, G. / Sisani, M. / Longo, F. et al. | 2015
- 2113
-
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial designGerety, E. L. / Lawrence, E. M. / Wason, J. / Yan, H. / Hilborne, S. / Buscombe, J. / Cheow, H. K. / Shaw, A. S. / Bird, N. / Fife, K. et al. | 2015
- 2119
-
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) studyLibé, R. / Borget, I. / Ronchi, C. L. / Zaggia, B. / Kroiss, M. / Kerkhofs, T. / Bertherat, J. / Volante, M. / Quinkler, M. / Chabre, O. et al. | 2015
- 2125
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsNieto, Y. / Tu, S. M. / Bassett, R. / Jones, R. B. / Gulbis, A. M. / Tannir, N. / Kingham, A. / Ledesma, C. / Margolin, K. / Holmberg, L. et al. | 2015
- 2133
-
Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factorsSprauten, M. / Haugnes, H. S. / Brydøy, M. / Kiserud, C. / Tandstad, T. / Bjøro, T. / Bjerner, J. / Cvancarova, M. / Fosså, S. D. / Oldenburg, J. et al. | 2015
- 2141
-
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancerDijkgraaf, E. M. / Santegoets, S. J. / Reyners, A. K. / Goedemans, R. / Wouters, M. C. / Kenter, G. G. / van Erkel, A. R. / van Poelgeest, M. I. / Nijman, H. W. / van der Hoeven, J. J. et al. | 2015
- 2149
-
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trialUeda, T. / Morioka, H. / Nishida, Y. / Kakunaga, S. / Tsuchiya, H. / Matsumoto, Y. / Asami, Y. / Inoue, T. / Yoneda, T. et al. | 2015
- 2155
-
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS riskSpina, M. / Nagy, Z. / Ribera, J. M. / Federico, M. / Aurer, I. / Jordan, K. / Borsaru, G. / Pristupa, A. S. / Bosi, A. / Grosicki, S. et al. | 2015
- 2161
-
Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?Ning, J. / Peng, S. / Ueno, N. / Xu, Y. / Shih, Y. / Karuturi, M. / Giordano, S. / Shen, Y. et al. | 2015
- 2168
-
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†Bompas, E. / Le Cesne, A. / Tresch-Bruneel, E. / Lebellec, L. / Laurence, V. / Collard, O. / Saada-Bouzid, E. / Isambert, N. / Blay, J. Y. / Amela, E. Y. et al. | 2015
- 2173
-
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaMiddleton, M. R. / Friedlander, P. / Hamid, O. / Daud, A. / Plummer, R. / Falotico, N. / Chyla, B. / Jiang, F. / McKeegan, E. / Mostafa, N. M. et al. | 2015
- 2180
-
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer modelMaia, A. R. / de Man, J. / Boon, U. / Janssen, A. / Song, J. Y. / Omerzu, M. / Sterrenburg, J. G. / Prinsen, M. B. / Willemsen-Seegers, N. / de Roos, J. A. et al. | 2015
- 2193
-
Health care in the United States—basic human right or entitlement?Jones, G. H. / Kantarjian, H. et al. | 2015
- 2196
-
Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapySiva, S. / Senan, S. / Ball, D. et al. | 2015
- 2196
-
Reply to the letter to the editor ‘Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy’ by Siva et al.de Baère, T. / Aupérin, A. / Deschamps, F. / Chevallier, P. / Gaubert, Y. / Boige, V. / Fonck, M. / Escudier, B. / Palussiére, J. et al. | 2015
- 2197
-
Primum non nocereTempleton, A. J. / Šeruga, B. et al. | 2015
- 2198
-
Reply to letter to the editor ‘Primum non nocere’ by Templeton and ŠerugaAapro, M. / Moebus, V. / Nitz, U. / O'Shaughnessy, J. / Pronzato, P. / Untch, M. / Tomita, D. / Bohac, C. / Leyland-Jones, B. et al. | 2015
- 2199
-
MiR-29c downregulation contributes to metastatic progression in colorectal cancerCristóbal, I. / Madoz-Gúrpide, J. / Manso, R. / Rojo, F. / García-Foncillas, J. et al. | 2015
- 2199
-
Reply to the letter to the editor ‘Flaws in the trial design of IFCT-0802’ by Gyawali et al.Pujol, J. L. / Morin, F. / Zalcman, G. et al. | 2015
- 2200
-
Reply to the letter to the editor ‘Journey to a faraway land’ by Alkan et al.Hartkopf, A. D. / Brucker, S. Y. / Taran, F. A. et al. | 2015
- 2200
-
Journey to a faraway landAlkan, A. / Karcı, E. / Utkan, G. et al. | 2015
- 2203
-
Is chemotherapy still an option in the treatment of melanoma?Carlino, M. S. / Long, G. V. et al. | 2015
- 2205
-
Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysisIbrahim, M. F. / Mazzarello, S. / Shorr, R. / Vandermeer, L. / Jacobs, C. / Hilton, J. / Hutton, B. / Clemons, M. et al. | 2015
- 2213
-
Why has active immunotherapy not worked in lung cancer?Thomas, A. / Giaccone, G. et al. | 2015
- 2221
-
Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature reviewSchmid, S. / Omlin, A. / Blum, D. / Strasser, F. / Gillessen, S. / Rothermundt, C. et al. | 2015
- 2247
-
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsDimopoulos, M. A. / Sonneveld, P. / Siegel, D. / Palumbo, A. / San-Miguel, J. et al. | 2015
- 2257
-
Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studiesGenkinger, J. M. / Kitahara, C. M. / Bernstein, L. / Berrington de Gonzalez, A. / Brotzman, M. / Elena, J. W. / Giles, G. G. / Hartge, P. / Singh, P. N. / Stolzenberg-Solomon, R. Z. et al. | 2015
- 2267
-
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaHersh, E. M. / Del Vecchio, M. / Brown, M. P. / Kefford, R. / Loquai, C. / Testori, A. / Bhatia, S. / Gutzmer, R. / Conry, R. / Haydon, A. et al. | 2015
- 2274
-
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502Sadahiro, S. / Tsuchiya, T. / Sasaki, K. / Kondo, K. / Katsumata, K. / Nishimura, G. / Kakeji, Y. / Baba, H. / Sato, S. / Koda, K. et al. | 2015
- 2280
-
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialDavidson, A. / Veillard, A. S. / Tognela, A. / Chan, M. M. / Hughes, B. G. / Boyer, M. / Briscoe, K. / Begbie, S. / Abdi, E. / Crombie, C. et al. | 2015
- 2286
-
A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†Dingemans, A. M. / Groen, H. J. / Herder, G. J. / Stigt, J. A. / Smit, E. F. / Bahce, I. / Burgers, J. A. / van den Borne, B. E. / Biesma, B. / Vincent, A. et al. | 2015
- 2293
-
High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriersCastro, E. / Jugurnauth-Little, S. / Karlsson, Q. / Al-Shahrour, F. / Piñeiro-Yañez, E. / Van de Poll, F. / Leongamornlert, D. / Dadaev, T. / Govindasami, K. / Guy, M. et al. | 2015
- 2300
-
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trialLee, J. L. / Kim, M. K. / Park, I. / Ahn, J. H. / Lee, D. H. / Ryoo, H. M. / Song, C. / Hong, B. / Hong, J. H. / Ahn, H. et al. | 2015
- 2305
-
Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivorsBoer, H. / Proost, J. H. / Nuver, J. / Bunskoek, S. / Gietema, J. Q. / Geubels, B. M. / Altena, R. / Zwart, N. / Oosting, S. F. / Vonk, J. M. et al. | 2015
- 2311
-
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†Casulo, C. / Day, B. / Dawson, K. L. / Zhou, X. / Flowers, C. R. / Farber, C. M. / Hainsworth, J. D. / Cerhan, J. R. / Link, B. K. / Zelenetz, A. D. et al. | 2015
- 2317
-
Life expectancy of young adults with follicular lymphomaConconi, A. / Lobetti-Bodoni, C. / Montoto, S. / Lopez-Guillermo, A. / Coutinho, R. / Matthews, J. / Franceschetti, S. / Bertoni, F. / Moccia, A. / Rancoita, P. M. et al. | 2015
- 2323
-
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaGraf, S. A. / Stevenson, P. A. / Holmberg, L. A. / Till, B. G. / Press, O. W. / Chauncey, T. R. / Smith, S. D. / Philip, M. / Orozco, J. J. / Shustov, A. R. et al. | 2015
- 2329
-
Histologic transformation in marginal zone lymphomas†Conconi, A. / Franceschetti, S. / Aprile von Hohenstaufen, K. / Margiotta-Casaluci, G. / Stathis, A. / Moccia, A. A. / Bertoni, F. / Ramponi, A. / Mazzucchelli, L. / Cavalli, F. et al. | 2015
- 2335
-
Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutritionBozzetti, F. / Cotogni, P. / Lo Vullo, S. / Pironi, L. / Giardiello, D. / Mariani, L. et al. | 2015
- 2341
-
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumorsde Braud, F. / Cascinu, S. / Spitaleri, G. / Pilz, K. / Clementi, L. / Liu, D. / Sikken, P. / De Pas, T. et al. | 2015
- 2347
-
Oncology 2020: a drug development and approval paradigmDhingra, K. et al. | 2015
- 2351
-
Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler methodHida, A. I. / Ohi, Y. et al. | 2015
- 2352
-
New life for retrospective study in the precision oncology eraOrlandi, A. / Basso, M. / Calegari, M. A. / Barone, C. et al. | 2015
- 2352
-
Adjuvant chemotherapy after preoperative chemoradiotherapy for rectal cancerKanyilmaz, G. / Koc, M. / Aktan, M. et al. | 2015
- 2353
-
Reply to the letter to the editor ‘New life for retrospective study in the Precision Oncology Era’ by Orlandi et al.Pietrantonio, F. / Cremolini, C. et al. | 2015
- 2354
-
Management of advanced prostate cancervon Eyben, F. / Kiljunen, T. / Kangasmaki, A. / Kairemo, K. / von Eyben, R. / Joensuu, T. et al. | 2015
- 2354
-
Reply to the letter to the editor ‘Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015’ by Gillessen et al.Gillessen, S. / Fanti, S. / Omlin, A. et al. | 2015
- 2355
-
Hemorrhagic cystitis in a patient without a past history of radiation therapy who was treated with cabazitaxel for CRPCKosaka, T. / Oya, M. et al. | 2015
- 2356
-
Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohortBishton, M. J. / Hubbard, R. / Witherall, R. / Jones, S. G. / Richardson, F. / James, E. J. / Sovani, V. / Bessell, E. M. / Haynes, A. P. / McMillan, A. K. et al. | 2015
- 2357
-
The ESMO magnitude of clinical benefit scaling tool: from theory to practiceHartmann, M. et al. | 2015
- 2359
-
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumoursLévy, C. / Allouache, D. / Lacroix, J. / Dugué, A. E. / Supiot, S. / Campone, M. / Mahe, M. / Kichou, S. / Leheurteur, M. / Hanzen, C. et al. | 2015
- 2361
-
Immunity and HER2-positive disease: never stop questioningLoi, S. et al. | 2015
- 2363
-
Statistical controversies in clinical research: long-term follow-up of clinical trials in cancerCuzick, J. et al. | 2015
- 2367
-
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic eraMartin, S. D. / Coukos, G. / Holt, R. A. / Nelson, B. H. et al. | 2015
- 2375
-
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesNaidoo, J. / Page, D. B. / Li, B. T. / Connell, L. C. / Schindler, K. / Lacouture, M. E. / Postow, M. A. / Wolchok, J. D. et al. | 2015
- 2392
-
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†Kramar, A. / Negrier, S. / Sylvester, R. / Joniau, S. / Mulders, P. / Powles, T. / Bex, A. / Bonnetain, F. / Bossi, A. / Bracarda, S. et al. | 2015
- 2398
-
Breastfeeding and breast cancer risk by receptor status—a systematic review and meta-analysisIslami, F. / Liu, Y. / Jemal, A. / Zhou, J. / Weiderpass, E. / Colditz, G. / Boffetta, P. / Weiss, M. et al. | 2015
- 2408
-
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studiesLambertini, M. / Ceppi, M. / Poggio, F. / Peccatori, F. A. / Azim, H. A. / Ugolini, D. / Pronzato, P. / Loibl, S. / Moore, H. C. / Partridge, A. H. et al. | 2015
- 2419
-
Designs of preoperative biomarkers trials in oncology: a systematic review of the literatureMarous, M. / Bièche, I. / Paoletti, X. / Alt, M. / Razak, A. R. / Stathis, A. / Kamal, M. / Le Tourneau, C. et al. | 2015
- 2429
-
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trialBianchini, G. / Pusztai, L. / Pienkowski, T. / Im, Y. H. / Bianchi, G. V. / Tseng, L. M. / Liu, M. C. / Lluch, A. / Galeota, E. / Magazzù, D. et al. | 2015
- 2437
-
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRNLeonard, R. C. / Mansi, J. L. / Keerie, C. / Yellowlees, A. / Crawford, S. / Benstead, K. / Matthew, R. / Adamson, D. / Chan, S. / Grieve, R. et al. | 2015
- 2442
-
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialMunzone, E. / Giobbie-Hurder, A. / Gusterson, B. A. / Mallon, E. / Viale, G. / Thürlimann, B. / Ejlertsen, B. / MacGrogan, G. / Bibeau, F. / Lelkaitis, G. et al. | 2015
- 2450
-
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsSunakawa, Y. / Stintzing, S. / Cao, S. / Heinemann, V. / Cremolini, C. / Falcone, A. / Yang, D. / Zhang, W. / Ning, Y. / Stremitzer, S. et al. | 2015
- 2457
-
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinomaKang, Y. K. / Yau, T. / Park, J. W. / Lim, H. Y. / Lee, T. Y. / Obi, S. / Chan, S. L. / Qin, S. / Kim, R. D. / Casey, M. et al. | 2015
- 2464
-
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancerMiddleton, G. / Crack, L. R. / Popat, S. / Swanton, C. / Hollingsworth, S. J. / Buller, R. / Walker, I. / Carr, T. H. / Wherton, D. / Billingham, L. J. et al. | 2015
- 2470
-
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancerMichels, J. / Adam, J. / Goubar, A. / Obrist, F. / Damotte, D. / Robin, A. / Alifano, M. / Vitale, I. / Olaussen, K. A. / Girard, P. et al. | 2015
- 2477
-
Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancerTakeda, M. / Sakai, K. / Terashima, M. / Kaneda, H. / Hayashi, H. / Tanaka, K. / Okamoto, K. / Takahama, T. / Yoshida, T. / Iwasa, T. et al. | 2015
- 2483
-
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaNowak, A. K. / Cook, A. M. / McDonnell, A. M. / Millward, M. J. / Creaney, J. / Francis, R. J. / Hasani, A. / Segal, A. / Musk, A. W. / Turlach, B. A. et al. | 2015
- 2490
-
Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institutionHosing, C. / Bassett, R. / Dabaja, B. / Talpur, R. / Alousi, A. / Ciurea, S. / Popat, U. / Qazilbash, M. / Shpall, E. J. / Oki, Y. et al. | 2015
- 2496
-
Alopecia in patients treated with molecularly targeted anticancer therapiesBelum, V. R. / Marulanda, K. / Ensslin, C. / Gorcey, L. / Parikh, T. / Wu, S. / Busam, K. J. / Gerber, P. A. / Lacouture, M. E. et al. | 2015
- 2503
-
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancerSchirripa, M. / Loupakis, F. / Lonardi, S. / Cremolini, C. / Bergamo, F. / Zagonel, V. / Falcone, A. et al. | 2015
- 2504
-
Comment on ESMO Magnitude of Clinical Benefit ScaleMuhonen, T. / Joensuu, H. / Pfeiffer, P. et al. | 2015
- i1
-
5P RELIABLE EGFR MUTATION TESTING IN ULTRASOUND GUIDED SUPRACLAVICULAR LYMPH NODE FINE NEEDLE ASPIRATES: A COHORT STUDY WITH DIAGNOSTIC PERFORMANCE ANALYSISAwwad, A. / Tiwari, S. / Sovani, V. / Baldwin, D. / Kumaran, M. et al. | 2015
- i1
-
1PD AN INTEGRATIVE ANALYSIS OF THE PUTATIVE GEFITINIB-RESISTANT GENES IN A LUNG CANCER CELL LINE MODEL SYSTEMHan, X. / Liu, M. / Wang, S. / Qian, X. / Lv, G. / Ma, L. / Zeng, C. / Shi, Y. et al. | 2015
- i1
-
3P EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER IN SOUTH AFRICAChan, S. W. / Maske, C. P. / Ruff, P. et al. | 2015
- i1
-
2P EGFR MUTATION IS NOT A RARE ISSUE FOR PERIPHERAL SQUAMOUS CARCINOMA OF LUNGZhang, Q. / Zhu, L. / Gu, P. / Zhang, Y. / Han, B. / Zhang, J. et al. | 2015
- i2
-
8P PD1/PD-L1 EXPRESSION IN NSCLC DIFFERS ACCORDING TO LOCALISATION, GRADING AND SUBTYPEBr�hl, F. / Csanadi, A. / Kayser, C. / Wiesemann, S. / Rawluk, J. / Werner, M. / Kayser, G. et al. | 2015
- i2
-
6P SCREENING FOR THE PREVALENCE OF EGFR AND ALK MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS IN THE LEVANT AREA, A PROSPECTIVE ANALYSISTfayli, A. / Khalil, M. / Mina, A. / Rafei, H. / Fakhreddin, N. / Mahfouz, R. / Farhat, F. / Hamouri, S. / Dbouk, H. / Zaatari, G. et al. | 2015
- i2
-
7P FREQUENCY OF ALK GENE REARRANGEMENT IN SAUDI LUNG CANCERAl Dayel, F. H. / Al Husaini, H. / Mohammed, S. / Tulbah, A. / Al Kuraya, K. et al. | 2015
- i3
-
11P THE COMPARATIVE ESTIMATION OF ESTROGEN RECEPTOR BETA EXPRESSION IN PRIMARY AND METASTATIC LUNG CANCERBogush, T. A. / Dudko, E. A. / Bogush, E. A. / Kirsanov, V. J. / Grishanina, A. N. / Ramanauskaite, R. J. / Polotsky, B. E. / Tjulandin, S. / Davydov, M. I. et al. | 2015
- i3
-
9P DISTRIBUTION OF T CELLS IN NON-SMALL CELL LUNG CANCER TISSUE ACCORDING TO COPD AND SMOKING STATUSJackute, J. / Zemaitis, M. / Pranys, D. / Sitkauskiene, B. / Miliauskas, S. / Sakalauskas, R. et al. | 2015
- i3
-
12P A MOLECULAR CASECONTROL INVESTIGATION OF THE MERKEL CELL POLYOMAVIRUS PREVALENCE IN VIETNAMESE NON-SMALL-CELL LUNG-CANCERNgo, T. T. et al. | 2015
- i3
-
10P ALLELE FREQUENCY OF ABO AND RH BLOOD GROUP AND THE RISK OF NON SMALL CELL LUNG CARCINOMAKapoor, A. / Kumar, N. / Kalwar, A. / Narayan, S. / Nirban, R. K. / Jakhar, S. L. / Beniwal, S. K. / Sharma, N. / Kumar, H. S. / Sharma, A. et al. | 2015
- i4
-
16P COMPREHENSIVE ANALYSIS OF DRIVER MUTATIONS IN CHINESE SQUAMOUS CELL LUNG CARCINOMAS BY TARGETED NEXT-GENERATION SEQUENCINGShi, Y. / Tao, D. / Yang, S. / Han, X. / Wu, D. / Zhang, N. et al. | 2015
- i4
-
13P EXPRESSION OF IRAK-1 AND EZH-2 IN IMPRINTS OF NSCLC AND PRENEOPLASTIC LESIONSHainis, K. / Athanassiadou, A. M. / Haini, E. / Tsipis, A. / Gonidi, M. / Athanassiadou, P. et al. | 2015
- i4
-
14P DIFFERENT TREND IN MULTIPLE PRIMARY LUNG CANCER AND INTRAPULMONARY METASTASISShen, C. / Che, G. et al. | 2015
- i4
-
15P CLINICOPATHOLOGICAL ANALYSIS OF PRIMARY PULMONARY LYMPHOEPITHELIOMA-LIKE CARCINOMAShen, C. / Che, G. et al. | 2015
- i5
-
18P TARTRATE-RESISTANT ACID PHOSPHATASE ISOFORM 5B (TRACP 5B) AS SERUM MARKER OF BONE METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) AND BREAST CANCER. PRELIMINARY RESULTSLumachi, F. / Del Conte, A. / Mazza, F. / Basso, S. M. / Chiara, G. B. et al. | 2015
- i5
-
19P FINE NEEDLE ASPIRATION CYTOLOGY OF THYMIC EPITHELIAL NEOPLASMS: A CYTOLOGIC-HISTOLOGIC CORRELATION ANALYSIS FROM A REFERRAL INSTITUTIONTemplo, F. J. et al. | 2015
- i5
-
17P IDENTIFYING THE GENETIC LANDSCAPE OF SQUAMOUS CELL CARCINOMA (SCC) AND ADENOSQUAMOUS CARCINOMA (ASC) OF THE LUNG USING NEXT-GENERATION SEQUENCING (NGS)Chilingirova, N. / Balabanski, L. / Toncheva, D. / Kurteva, G. / Damyanov, D. / Chilingirov, P. et al. | 2015
- i6
-
22PD BODY MASS INDEX AND LUNG CANCER SURVIVAL: RESULTS FROM THE ICARE STUDYSanikini, H. / Clain, G. / Sanchez, M. / Guizard, A. V. / Woronoff, A. S. / Tretarre, B. / Molinie, F. / Delafosse, P. / Luce, D. / St�cker, I. et al. | 2015
- i6
-
20PD PASSIVE SMOKE EXPOSURE IS NOT A SIGNIFICANT RISK FACTOR IN THE DEVELOPMENT OF LUNG CANCERVirdi, R. P. / Fisher, J. M. / Balekian, A. A. et al. | 2015
- i7
-
25P A COMMON BIM DELETION POLYMORPHISM WAS ASSOCIATED WITH THE RISK OF LUNG CANCER IN A CHINESE POPULATIONJing, X. J. et al. | 2015
- i7
-
26PD THE EFFECT OF EMERGENCY PRESENTATION ON SURGERY AND SURVIVAL IN LUNG CANCER PATIENTS IN ENGLAND, 2006-2008Tataru, D. / Jack, R. H. / M�ller, H. / L�chtenborg, M. et al. | 2015
- i7
-
23PD INTERSTITIAL LUNG DISEASE ON CHEST COMPUTED TOMOGRAPHY IS ASSOCIATED WITH THE DEVELOPMENT OF LUNG CANCERKakal, K. / Fisher, J. M. / Balekian, A. A. et al. | 2015
- i7
-
24PD PREDICTING EARLY LUNG CANCER USING BIG DATAGe, Y. / Ma, L. / Tao, L. W. / Han, M. F. / Ma, L. M. et al. | 2015
- i8
-
28P SEX DIFFERENCES IN PRESENTATION, MANAGEMENT AND PROGNOSIS OF MOROCCAN PATIENTS WITH NON SMALL CELL LUNG CARCINOMA: A RETROSPECTIVE ANALYSIS OF 224 CASESAmaadour, L. / Boudahna, L. / Benbrahim, Z. / Arifi, S. / Mellas, N. et al. | 2015
- i8
-
29P THE RISK OF LUNG CANCER AMONG WOMEN WHO START SMOKING AS TEENAGERSTagbarha, M. O. et al. | 2015
- i8
-
27P CHARACTERISTICS OF LUNG CANCER DIAGNOSED WITH LOW DOSE CHEST CT SCREENINGChoi, S. / Lee, C. et al. | 2015
- i8
-
31P PLASMA CRABP2 IN PATIENTS WITH NON-SMALL CELL LUNG CANCERHan, S. S. / Lee, H. Y. / Lee, S. J. / Kim, W. J. / Hong, Y. / Lee, E. J. et al. | 2015
- i8
-
30P THE BELIEFS, ORIENTATION, KNOWLEDGE, UNDERSTANDING, ATTITUDES AND TREATMENT ACCESS TO LUNG CANCER AMONGST RURAL MEN IN NIGERIATagbarha, M. O. et al. | 2015
- i9
-
32P EPIDEMIOLOGY, TREATMENT PATTERNS AND SURVIVAL OUTCOME IN PATIENTS OF ADVANCED STAGE INOPERABLE LUNG CANCER: A TERTIARY CANCER CARE CENTRE ANALYSISKumar, D. / Pant, M. C. / Singh, S. et al. | 2015
- i9
-
33P IDIOPATHIC PULMONARY FIBROSIS AS A POOR PROGNOSTIC FACTOR IN LUNG CANCER PATIENTSSon, C. / Um, S. / Roh, M. S. et al. | 2015
- i10
-
37PD SNPS IN ANGIOGENIC FACTORS AS PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS (P) WITH ADVANCED NON-SQUAMOUS NSCLC (NS-NSCLC) TREATED WITH CARBOPLATIN, PACLITAXEL (CP) AND BEVACIZUMAB (BEV). FINAL RESULTS OF ANGIOMET SPANISH LUNG CANCER GROUP TRIALMassuti Sureda, B. / Jantus-Lewintre, E. / Gonzalez-Larriba, J. L. / Rodriguez Abreu, D. / Juan, O. J. / Domine, M. / Provencio Pulla, M. / de Castro, J. / Camps, C. / Rosell, R. et al. | 2015
- i10
-
36O DETECTION OF EGFR T790M MUTATION IN URINARY CIRCULATING TUMOR DNA FROM METASTATIC NON-SMALL CELL LUNG CANCER PATIENTSHusain, H. / Kosco, K. / Guerrero, S. / Lu, T. T. / Vibat, C. R. / Erlander, M. G. / Melnikova, V. et al. | 2015
- i10
-
38PD CT CHARACTERISTICS ALLOW THE IDENTIFICATION OF PATIENT-SPECIFIC AND REGIONAL SUSCEPTIBILITY FOR RADIATION-INDUCED LUNG DAMAGEDefraene, G. / van Elmpt, W. / Crijns, W. / Slagmolen, P. / De Ruysscher, D. et al. | 2015
- i11
-
41P THE COMPARATIVE ESTIMATION OF TUBB3 EXPRESSION IN NON-SMALL-CELL LUNG CARCINOMA AND ADJACENT LUNG TISSUEBogush, T. A. / Mamichev, I. A. / Dudko, E. A. / Grishanina, A. N. / Ramanauskaite, R. J. / Vichljantzeva, N. O. / Tjulandin, S. / Polotsky, B. E. / Davydov, M. I. et al. | 2015
- i11
-
42P BIOLOGICAL ROLE OF PROGNOSTIC MICRORNAS (MIRNAS) IN SQUAMOUS LUNG CARCINOMA (SCC) CELLSFilipska, M. / Skrzypski, M. / Stasi?oj?, G. / Bigda, J. et al. | 2015
- i11
-
39O IMMUNE CHECKPOINTS SCORE AND CD8+ T CELLS INFILTRATION ARE INDEPENDENT PROGNOSTIC BIOMARKERS IN RESECTED NSCLCUs�, M. / Jantus-Lewintre, E. / Sirera, R. / Calabuig-Fari�as, S. / Blasco, A. / Guijarro, R. / Forteza, J. / Camps, C. et al. | 2015
- i12
-
46P ANTITUMOR EFFICACY OF THE DOUBLE SUICIDE GENES IN LUNG CANCER CELLSShen, C. / Che, G. et al. | 2015
- i12
-
44P UPREGULATED MIRNA 21 IN KRAS MUTATED PATIENTS IS RELATED TO PROGNOSIS IN RESECTABLE NON-SMALL CELL LUNG CANCERGallach, S. / Calabuig-Fari�as, S. / Jantus-Lewintre, E. / Montaner, D. / Escorihuela, E. / Blasco, A. / Guijarro, R. / Camps, C. et al. | 2015
- i12
-
43P MIR31-3P EXPRESSION IN PATIENTS WITH ADVANCED LEPIDIC ADENOCARCINOMA (L-ADC) TREATED WITH EGFR TKI IN IFCT 0401 AND 0504 TRIALSThiebaut, R. / Wislez, M. / Vazart, C. / Decaulne, V. / Mazieres, J. / Friard, S. / Merle, P. / Morin, F. / Liebaert, F. / Cadranel, J. et al. | 2015
- i12
-
45P MICRORNA EXPRESSION PROFILING IN LUNG CANCER AND NORMAL TISSUE USING MASSIVELY PARALLEL SEQUENCING TECHNIQUELee, H. Y. / Song, S. Y. / Lim, K. H. / Lee, S. J. / Han, S. S. / Kim, W. J. et al. | 2015
- i13
-
48P DEVELOPMENT OF RESISTANCE MODELS TO TYROSINE KINASE INHIBITORS (TKIS) IN PATIENT-DERIVED XENOGRAFT MODELS (PDXS) OF LUNG ADENOCARCINOMA WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONSStewart, E. L. / Sakashita, S. / Wang, T. / Pham, N. A. / Li, M. / Liu, G. / Tsao, M. S. et al. | 2015
- i13
-
49P SYNERGISTIC EFFECT OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN EGFR-TKI RESISTANT NON-SMALL CELL LUNG CANCER CELL LINESHan, X. / Zhang, N. / Yao, J. / Shi, Y. et al. | 2015
- i13
-
47P PHARMACOGENETICS & TREATMENT OUTCOME IN CANCER PATIENTS RECEIVING RADIO-CHEMOTHERAPYYadav, S. S. / Chauhan, V. / Parmar, D. et al. | 2015
- i14
-
50P ENUMERATION AND MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS IN LUNG CANCER PATIENTS USING THE GILUPI CELLCOLLECTOR, AN EFFECTIVE IN VIVO DEVICE FOR CAPTURING CTCSScheumann, N. / Gorges, T. / Penkalla, N. / Nowack, B. / Schalk, T. / Riethdorf, S. / L�cke, K. / Pantel, K. / Krahn, T. / Schumann, C. et al. | 2015
- i14
-
52P MULTIPARAMETER PLOIDY PROFILING: A POWERFUL TOOL TO INVESTIGATE THE GENOMICS OF DIPLOID TUMOR POPULATIONSLorber, T. / Rau, S. / Perrina, V. / Barrett, M. / Ruiz, C. / Bubendorf, L. et al. | 2015
- i14
-
51P GEF GENE: A NEW SUICIDE GENE THERAPY FOR NON-SMALL CELL LUNG CANCERRama Ballesteros, A. R. / Hern�ndez, R. / Perazzoli, G. / Oliver, J. / Cabeza, L. / Jim�nez-Luna, C. / Leiva, M. C. / Jim�nez, J. / Prados, J. et al. | 2015
- i15
-
55P PROPOSED NEW SIMPLE CRITERIA OF CLINICAL MULTIPLE PRIMARY LUNG CANCERSMatsunaga, T. / Suzuki, K. / Takamochi, K. / Oh, S. et al. | 2015
- i15
-
56P FDG PET/CT FOR EVALUATION OF MEDIASTINAL LYMPH NODE STAGING USING FDG UPTAKE AND VOLUMETRIC CT HISTOGRAM IN NON-SMALL CELL LUNG CANCERLee, J. W. / Lee, S. M. / Lee, J. H. et al. | 2015
- i15
-
53O IS ROUTINE SAMPLING OF THE INFERIOR MEDIASTINAL LYMPH NODE STATIONS A NECESSITY FOR PRE-OPERATIVE MEDIASTINAL STAGING IN LUNG CANCER? RESULTS OF A LARGE RETROSPECTIVE STUDY OF 986 SURGICAL RESECTIONSEvison, M. / Britton, S. / Al-Najjar, H. / Crosbie, P. / Bishop, P. / Jones, M. / Krysiak, P. / Rammohan, K. / Shah, R. / Booton, R. et al. | 2015
- i15
-
54PD ADVANTAGES OF DIFFUSION WEIGHTED IMAGING OF PULMONARY NODULES AND MASSES: COMPARISON WITH POSITRON EMISSION TOMOGRAPHYUsuda, K. / Sagawa, M. / Motono, N. / Ueno, M. / Tanaka, M. / Machida, Y. / Maeda, S. / Matoba, M. / Tonami, H. / Ueda, Y. et al. | 2015
- i17
-
58P RADIATION THERAPY (RT) IN THE PALLIATIVE TREATMENT OF METASTATIC SMALL CELL LUNG CANCER (SCLC)Ragulin, Y. / Ivanova, I. / Gulidov, I. / Mardynsky, Y. / Zolotkov, A. / Gogolin, D. / Kursova, L. et al. | 2015
- i17
-
57P INHIBITION OF THE FOCAL ADHESION KINASE HAS ANTI-TUMORAL EFFECT IN SMALL-CELL LUNG CANCER CELL LINESAboubakar, F. / Lecocq, M. / Detry, B. / Maha, L. / Massion, P. P. / Sibille, Y. / Pilette, C. / Ocak, S. et al. | 2015
- i18
-
62O THIRTY AND 90-DAY MORTALITY AFTER LUNG CANCER RESECTION IN 2242 PATIENTSFrick, A. E. / L�ders, H. / Leschber, G. et al. | 2015
- i18
-
60O ANALYSIS OF LOCAL RECURRENCES FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR): DATA FROM A LARGE INSTITUTIONAL DATABASEVerstegen, N. E. / Lagerwaard, F. J. / Slotman, B. J. / Dahele, M. / Senan, S. et al. | 2015
- i18
-
61O OUTCOME OF SURGICAL SALVAGE FOR LOCAL FAILURES FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)Verstegen, N. E. / Lagerwaard, F. J. / Paul, M. A. / Smit, E. F. / Versteegh, M. I. / Joosten, J. J. / Slotman, B. J. / Senan, S. et al. | 2015
- i19
-
63PD COMPARISON OF CLINICAL OUTCOME OF STAGE I NON-SMALL CELL LUNG CANCER TREATED SURGICALLY OR WITH STEREOTACTIC RADIOTHERAPY: RESULTS FROM PROPENSITY SCORE ANALYSISMokhles, S. / Verstegen, N. E. / Maat, A. P. / Birim, O. / Bogers, A. J. / Mokhles, M. M. / Lagerwaard, F. J. / Senan, S. / Takkenberg, J. J. et al. | 2015
- i19
-
64PD EFFECT OF COMORBIDITY ON SURGERY AND SURVIVAL AMONG LUNG CANCER PATIENTS IN ENGLANDL�chtenborg, M. / Riaz, S. P. / Jack, R. H. / Peake, M. D. / Lind, M. J. / M�ller, H. et al. | 2015
- i19
-
66P PROGNOSTIC CLASSIFICATION OF LUNG ADENOCARCINOMA BY INTEGRATED MIRNA-MRNA EXPRESSION PROFILESTam, S. / Pintilie, M. / Liu, N. / McPherson, J. D. / Tsao, M. S. et al. | 2015
- i19
-
65PD PROGNOSTIC INFLUENCE OF MUTATIONAL STATUS IN RESECTED NON-SMALL CELL LUNG CANCER: THE KRAS G12V WORSE VALUERenaud, S. / Falcoz, P. E. / Schaeffer, M. / Beau-Faller, M. / Romain, B. / Olland, A. / Reeb, J. / Santelmo, N. / Massard, G. / Voegeli, A. C. et al. | 2015
- i20
-
70P PROGNOSTIC ROLE OF T-REGULATORY CELLS IN COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CARCINOMAKose, F. / Abali, H. / F?nd?kc?oglu, A. / Canpolat, T. / Besen, A. A. / Sumbul, A. T. / Mertsoylu, H. / Sedef, A. M. / Ozyilkan, O. et al. | 2015
- i20
-
69P THE IMPACT OF GENETIC ALTERATION ON RECURRENCE IN PATIENTS WITH RESECTED STAGE I NON-SMALL CELL LUNG CANCERChung, H. S. / Heo, E. Y. / Park, S. S. / Park, Y. S. / Kim, Y. W. / Kim, D. K. et al. | 2015
- i20
-
68P THE UTILITY OF ACTININ-4 PROTEIN OVEREXPRESSION AS A PREDICTIVE BIOMARKER FOR THERAPEUTIC EFFECT OF ADJUVANT CHEMOTHERAPY TO THE RESECTED LUNG ADENOCARCINOMAShiraishi, H. / Fujiwara, Y. / Kakuya, T. / Tsuta, K. / Watanabe, S. / Huang, W. / Yamada, T. / Asamura, H. / Ohe, Y. / Honda, K. et al. | 2015
- i20
-
67P MRNA EXPRESSION LEVEL OF LYMPHANGIOGENESIS-ASSOCIATED GENES IN EARLY-STAGE NON-SMALL CEL LUNG CANCERKowalczuk, O. / Kozlowski, M. / Laudanski, W. / Kisluk, J. / Niklinski, J. et al. | 2015
- i21
-
73P OUTCOME OF EARLY-STAGE LUNG CANCER TREATED WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT)Alameddine, M. / Chan, J. / Pope, A. / Haridass, A. / Baker, A. / Meara, S. / Clements, R. / Crabtree, A. / Wong, H. / Eswar, C. et al. | 2015
- i21
-
74P DOES A HIGHER SURGICAL RESECTION RATE IN LUNG CANCER LEAD TO A HIGHER RATE OF POST-OPERATIVE MULTI-STATION N2 DISEASE?Evison, M. / Britton, S. / Al-Najjar, H. / Crosbie, P. / Bishop, P. / Jones, M. / Krysiak, P. / Rammohan, K. / Shah, R. / Booton, R. et al. | 2015
- i21
-
71P OUTCOME AFTER SBRT FOR POTENTIALLY OPERABLE NSCLC PATIENTSRossi, M. / Peulen, H. / van Tinteren, H. / Wouters, M. / Sonke, J. J. / Baas, P. / Smit, E. F. / Belderbos, J. et al. | 2015
- i21
-
72P OCCURRENCE OF SIGNIFICANT TUMOR VOLUME CHANGES DURING STEREOTACTIC BODY RADIATION THERAPY FOR LUNG CANCERCharlier, F. / Moretti, L. / Jourani, Y. / de Brouwer, T. / Van Houtte, P. et al. | 2015
- i22
-
78P EXAMINATION OF PROGNOSTIC FACTORS IN CASES RECEIVING UFT AS POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR LUNG CANCERNawa, K. / Yoneyama, R. / Kakihana, M. / Kajiwara, N. / Ohira, T. / Ikeda, N. et al. | 2015
- i22
-
77P POST-OPERATIVE OUTCOMES IN NON-SMALL CELL LUNG CANCER PATIENTS WITH MILD TO MODERATE STAGE CHRONIC OBSTRUCTIVE PULMONARY DISEASEItotani, R. / Marumo, S. / Kumagai, S. / Yamanashi, K. / Tokuno, J. / Sumitomo, R. / Shoji, T. / Huang, C. / Fukui, M. et al. | 2015
- i22
-
76P RESULT OF THE 6-MINUTE WALK TEST IS AN INDEPENDENT PROGNOSTIC FACTOR OF SURGICALLY TREATED NON-SMALL CELL LUNG CANCERMarjanski, T. / Badocha, M. / Wnuk, D. / Mosiewicz, A. / Rzyman, W. et al. | 2015
- i22
-
75P ADEQUACY OF LYMPH NODE SAMPLING DURING SURGICAL RESECTION OF LUNG CANCER AT A REGIONAL UK THORACIC SURGICAL CENTRE 2011-2013Evison, M. / Britton, S. / Al-Najjar, H. / Crosbie, P. / Jones, M. / Bishop, P. / Krysiak, P. / Rammohan, K. / Shah, R. / Booton, R. et al. | 2015
- i23
-
80P ROLE OF TREATMENT IN INTERNATIONAL DIFFERENCES IN ONE-YEAR MORTALITY FROM EARLY STAGE NON-SMALL CELL LUNG CANCER: A TENTATIVE ANSWER FROM THE INTERNATIONAL CANCER BENCHMARKING PARTNERSHIP STUDYSolomon, T. / Peake, M. D. / Butler, J. / Coleman, M. P. / Evans, W. K. / Jakobsen, E. / Boyer, M. / Johannesen, T. B. / Rachet, B. et al. | 2015
- i23
-
79P VOLUME CHANGES WITH HYPO-FRACTIONATED RADIOTHERAPY IN EARLY LUNG CANCER: TIME TRENDS & OUTCOMESPathak, R. S. / Tibdewal, A. R. / Ghosh Laskar, S. / Chaudhari, S. / Agarwal, J. P. et al. | 2015
- i24
-
81O ERLOTINIB AS NEOADJUVANT TREATMENT IN ENDOBRONCHIAL ULTRASOUND CONFIRMED STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (EXON 19 OR 21) (NCT01217619, ESTERN): A PROSPECTIVE, SINGLE ARM, PHASE II CLINICAL TRIALHan, B. / Xiong, L. / Sun, J. / Li, R. / Lou, Y. / Zhang, Y. / Gu, A. / Jiang, L. / Shi, J. et al. | 2015
- i24
-
82PD THE VOLUME MATTERS IN STAGE III NSCLC PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPYvan Diessen, J. / Chen, C. / Heemsbergen, W. / van den Heuvel, M. / Belderbos, J. / Sonke, J. J. et al. | 2015
- i24
-
83PD PROGNOSIS OF STAGE III NON-SMALL-CELL LUNG CANCER PATIENTS PRESENTING WITH ISOLATED BRAIN FAILURE AFTER DEFINITIVE CONCURRENT CHEMORADIATION THERAPYTopkan, E. / Guler, O. C. / Yildirim, B. A. et al. | 2015
- i25
-
84P TRIMODALITY THERAPY INCLUDING RADICAL RESECTION FOR PANCOAST TUMORS: T4 IS NOT A CONTRAINDICATION FOR RADICAL SURGERYHoda, M. A. / Waseda, R. / Klikovits, T. / Foesleitner, O. / Zoechbauer-Mueller, S. / Dieckmann, K. / Prosch, H. / Pirker, R. / Klepetko, W. et al. | 2015
- i25
-
85P REVIEW OF RADICAL RADIOTHERAPY +/- CHEMOTHERAPY FOR STAGE III NSCLCButton, M. / Evans, R. / Rees, E. M. / Bullock, C. et al. | 2015
- i25
-
86P CAN CONCURRENT CHEMO-RADIATION BE DELAYED BY INDUCTION CHEMOTHERAPY IN THE CURATIVE TREATMENT OF STAGE III NON-SMALL CELL LUNG CARCINOMA? A POOLED ANALYSISGuilbault, C. / Garant, A. / Almajed, M. / Faria, S. / Owen, S. / Duclos, M. / Ofiara, L. / Gruber, J. / Hirsh, V. / Kopek, N. et al. | 2015
- i26
-
90P CONCURRENT CHEMORADIOTHERAPY WITH VINORELBINE PLUS SPLIT-DOSE CISPLATIN IN INOPERABLE STAGE III NON-SMALL CELL LUNG CANCERMertsoylu, H. / Kose, F. / Sedef, A. M. / Dogan, O. / Parlak, C. / Besen, A. A. / Sumbul, A. T. / F?nd?kc?oglu, A. / Sezer, A. / Muallaoglu, S. et al. | 2015
- i26
-
89P CLINICAL FACTORS OF NODAL UPSTAGING IN PATHOLOGIC N1 OR N2 NON-SMALL CELL LUNG CANCERMoon, Y. / Sung, S. W. / Kim, K. S. / Park, J. K. et al. | 2015
- i26
-
88P OMISSION OF ELECTIVE NODAL IRRADIATION HAS NO IMPACT ON ISOLATED ELECTIVE NODAL FAILURE AND SURVIVAL OUTCOMES IN STAGE III NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH DEFINITIVE CONCURRENT CHEMORADIOTHERAPYTopkan, E. / Guler, O. C. / Yildirim, B. A. et al. | 2015
- i26
-
87P WHAT TO DO FOR THE TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) WITH A SINGLE MEDIASTINAL LYMPH NODE INVOLVEMENT (N2A DISEASE) IN DEVELOPING COUNTRIES?Caushi, F. / Hafizi, H. / Mezini, A. / Xhemalaj, D. / Skenduli, I. et al. | 2015
- i27
-
94P LUNG CANCER IN WOMEN, A DIFFERENT DISEASE: SURVIVAL DIFFERENCES BY SEXUlas, A. / Tokluoglu, S. T. / K�s, M. / Silay, K. / Akinci, S. / Oksuzoglu, B. O. / Alkis, N. et al. | 2015
- i27
-
93P THE CLINICAL CHARACTERISTICS OF 50 PATIENTS WITH RADIATION PNEUMONITISLiu, R. / Zhang, Q. / Wang, X. et al. | 2015
- i27
-
92P SOCIAL DEPRIVATION AND RADICAL TREATMENT OF STAGE III NSCLCButton, M. / Evans, R. / Bullock, C. / Rees, E. M. et al. | 2015
- i27
-
91P DEFINITIVE CONCOMITANT RADIOCHEMOTHERAPY (RCT) TREATMENT FOR LOCALLY ADVANCED (LA) NON SMALL CELL LUNG CANCER (NSCLC): EVALUATION OF HEMATOLOGICAL AND ESOPHAGEAL TOXICITY IN THE RADIATION ONCOLOGY DEPARTMENT OF UNIVERSITY OF FLORENCE EXPERIENCEScotti, V. / Scartoni, D. / Furfaro, I. F. / Simontacchi, G. / De Luca Cardillo, C. / Agresti, B. / Talamonti, C. / Livi, L. et al. | 2015
- i28
-
95TiP A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE 3 NSCLC WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)Creelan, B. / Iannotti, N. O. / Salamat, M. A. / Jayawardene, D. / Ballas, M. / Stockman, P. K. / Antonia, S. J. et al. | 2015
- i29
-
96O DETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDYHan, B. / Tjulandin, S. / Hagiwara, K. / Normanno, N. / Wulandari, L. / Konstantin Konstantinovich, L. / Hudoyo, A. / Ratcliffe, M. / McCormack, R. / Reck, M. et al. | 2015
- i30
-
97O EGFR MUTANT SUBSET ANALYSIS FROM ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF DACOMITINIB VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)Paz-Ares, L. / O'Byrne, K. / Mok, T. S. / Boyer, M. / J�nne, P. A. / Goldberg, Z. / Mather, C. / Taylor, I. / Zhang, H. / Ramalingam, S. S. et al. | 2015
- i30
-
99O PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSESRosell, R. / Gettinger, S. / Bazhenova, L. A. / Langer, C. J. / Salgia, R. / Gold, K. / Shaw, A. T. / Dorer, D. J. / Kerstein, D. / Camidge, D. R. et al. | 2015
- i31
-
100PD A PROSPECTIVE RANDOMIZED OPEN LABEL PHASE III STUDY OF MAINTENANCE GEMCITABINE VERSUS BEST SUPPORTIVE CARE FOLLOWING PLATINUM-PACLITAXEL CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCERJakhar, S. L. / Narayan, S. / Kapoor, A. / Beniwal, S. K. / Singhal, M. K. / Kumari, P. / Singh, G. / Kumari, S. / Kumar, H. S. / Bardia, M. R. et al. | 2015
- i31
-
102PD A RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCERMazieres, J. / Blais, N. / Juhasz, E. / Urban, L. / Orlov, S. / Qin, Q. / McKee, M. / Giranda, V. / Gorbunova, V. / Ramalingam, S. S. et al. | 2015
- i31
-
101PD A PROSPECTIVE RANDOMIZED OPEN LABEL PHASE III STUDY OF GEFTINIB VERSUS DOCETAXEL AS SECOND OR THIRD LINE THERAPY IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER IN ASIAN INDIANSKapoor, A. / Kumar, N. / Narayan, S. / Nirban, R. K. / Maharia, S. / Beniwal, S. K. / Jakhar, S. L. / Kumar, H. S. et al. | 2015
- i32
-
103PD SUBGROUP ANALYSIS OF ELDERLY PATIENTS IN SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF NECITUMUMAB (N) PLUS GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY VERSUS GC ALONE IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC)Thatcher, N. / Ciuleanu, T. E. / Ramlau, R. / Schumann, C. / Paz-Ares, L. / Depenbrock, H. / Nanda, S. / Chouaki, N. / Socinski, M. et al. | 2015
- i32
-
104PD PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)Zalcman, G. / Rizvi, N. A. / Lena, H. / Wolf, J. / Mazieres, J. / Antonia, S. J. / Minenza, E. / Planchard, D. / Lestini, B. J. / Ramalingam, S. S. et al. | 2015
- i33
-
107PD AFATINIB (A) PLUS PACLITAXEL (P) FOLLOWING PROGRESSION ON A MONOTHERAPY IN PATIENTS (PTS) WITH METASTATIC NONSMALL-CELL LUNG CANCER (NSCLC) WHO PREVIOUSLY BENEFITED FROM ERLOTINIB (E)/GEFITINIB (G): A GLOBAL RANDOMISED PHASE III TRIALLUX-LUNG 5 (LL5)Schuler, M. / Yang, J. C. / Park, K. / Chand, V. K. / Wang, B. / Planchard, D. et al. | 2015
- i33
-
106PD EGFR MUTATION DETECTION IN PLASMA OF LUNG TUMOR PATIENTS IN THE ABSENCE OF CONTRIBUTIVE TISSUE IS A RELEVANT ALTERNATIVE FOR PRESCRIPTION OF TYROSINE KINASE INHIBITORS IN A ROUTINE CLINICAL SETTINGDenis, M. G. / Masson, P. / Vall�e, A. / Pigeanne, T. / Lacroix, H. et al. | 2015
- i33
-
105PD TG4010 IMMUNOTHERAPY COMBINED WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS OF THE TIME STUDYQuoix, E. / Nemunaitis, J. / Papai, Z. / Lena, H. / Genet, D. / Louis, C. / Cobo, M. / Al Farhat, Y. / Marie-Bastien, B. / Limacher, J. M. et al. | 2015
- i34
-
108PD AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8), A PHASE III GLOBAL TRIALGoss, G. D. / Felip, E. / Cobo, M. / Lu, S. / Georgoulias, V. / Ardizzoni, A. / Gadgeel, S. / Wang, B. / Chand, V. K. / Soria, J. C. et al. | 2015
- i34
-
109PD OVERALL SURVIVAL (OS) WITH AFATINIB (A) VS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH NSCLC HARBOURING EGFR MUTATIONS (MUT): SUBGROUP ANALYSES BY RACE IN LUX-LUNG 3 (LL3) AND LUX-LUNG 6 (LL6)Schuler, M. / Yang, J. C. / Sequist, L. V. / Yamamoto, N. / Zhou, C. / Hu, C. P. / O'Byrne, K. / Hirsh, V. / Mok, T. S. / Wu, Y. L. et al. | 2015
- i35
-
111P CERITINIB TREATMENT OF PATIENTS (PTS) WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES: ASCEND-1 TRIAL EXPERIENCEKim, D. W. / Mehra, R. / Tan, D. / Felip, E. / Szczudlo, T. / Rodriguez Lorenc, K. / Sutradhar, S. / Shaw, A. T. et al. | 2015
- i35
-
110PD SINGLE ORGAN METASTATIC DISEASE, A NEW PROGNOSTIC FACTOR FOR OVERALL SURVIVAL (OS) IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)Hendriks, L. / Derks, J. L. / Postmus, P. E. / Damhuis, R. A. / Houben, R. M. / Troost, E. G. / Hochstenbag, M. M. / Smit, E. F. / Dingemans, A. M. et al. | 2015
- i35
-
112P EFFICACY AND SAFETY OF IMPRIME PGG, A NOVEL INNATE IMMUNE MODULATOR, IN COMBINATION WITH BEVACIZUMAB (BEV), CARBOPLATIN AND PACLITAXEL FOR THE 1ST-LINE TREATMENT OF STAGE IV NSCLCBraun, A. / Engel-Riedel, W. / Schneller, F. / Wolf, M. / Schuette, W. / Lowe, J. / Mattson, P. / Gargano, M. / Patchen, M. / Huhn, R. et al. | 2015
- i36
-
114P A PHASE 1B STUDY OF ANTI-DLL4 (DELTA-LIKE LIGAND 4) ANTIBODY DEMCIZUMAB (DEM) WITH PEMETREXED (PEM) AND CARBOPLATIN (CARBO) IN PATIENTS WITH 1ST-LINE NON-SQUAMOUS NSCLCDupont, J. / McKeage, M. / Kotasek, D. / Markman, B. / Hidalgo, M. / Millward, M. / Jameson, M. / Harris, D. / Stagg, R. / Hughes, B. et al. | 2015
- i36
-
116P CLINICAL CHARACTERISTICS AND RESPONSE TO EGFR TKI IN NEVER SMOKER SQUAMOUS LUNG CANCEREe, S. / Young, S. / Tan, E. H. / Lim, D. / Tan, G. S. / Jain, A. / Zeng, W. / Lim, T. / Takano, A. / Tan, D. et al. | 2015
- i36
-
113P ANLOTINIB AS THIRD-LINE TREATMENT IN PATIENTS WITH REFRACTORY ADVANCED NON-SMALL CELL LUNG CANCER: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL (NCT01924195)Han, B. / Li, K. / Zhao, Y. / Li, B. / Cheng, Y. / Zhou, J. / Lu, Y. / Shi, Y. / Wang, Z. / Jiang, L. et al. | 2015
- i36
-
115P KIF5B & CCDC6 RET IN LUNG CANCER: CLINICAL INSIGHTS AND RESPONSE TO PERSONALIZED BASED THERAPYSarfaty, M. / Moore, A. / Gottfried, M. / Katznelson, R. / Nechushtan, H. / Wolner, M. / Neiman, V. / Soussan-Gutman, L. / Dvir, A. / Peled, N. et al. | 2015
- i37
-
118P ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER: PHASE IIIB STUDYZaric, B. / Perin, B. / Cekic, M. / Rancic, M. / Kovcin, V. / Andric, Z. / Murtezani, Z. H. / Jovanovic, D. / Velinovic, M. / Markovic, M. et al. | 2015
- i37
-
119P REVERSIBLE VERSUS IRREVERSIBLE EGFR TYROSINE-KINASE INHIBITORS FOR NON-SMALL-CELL LUNG CANCER (NSCLC): A PRECLINICAL AND PHARMACOKINETIC COMPARISONLiederer, B. M. / Friess, T. / Shames, D. / Wright, M. / Hop, C. E. et al. | 2015
- i37
-
117P GERMAN COUNTRY-WIDE SURVEYS FROM 2012 AND 2014 ABOUT EGFR MUTATIONAL TESTING ALGORITHMS ADOPTED BY MEDICAL DOCTORS IN PATIENTS WITH NSCLCOstermann, H. / Ukena, D. / Radke, S. / Freitag, A. / H�rnig, S. et al. | 2015
- i38
-
124P PLATINUM BASED CHEMOTHERAPY FOR THE TREATMENT OF ELDERLY PATIENTS WITH METASTATIC NON SMALL CELL LUNG CARCINOMA: A RETROSPECTIVE ANALYSIS OF A SINGLE INSTITUTIONAmaadour, L. / Boudahna, L. / Benbrahim, Z. / Arifi, S. / Mellas, N. et al. | 2015
- i38
-
120P IS SWITCH MAINTENANCE THERAPY MANDATORY FOR EGFR MUTATED PATIENTS INITIATED ON CHEMOTHERAPY?Roy, R. et al. | 2015
- i38
-
122P ICOTINIB AS FIRST-LINE TREATMENT FOR ELDERLY PATIENTS WITH EGFR 19 OR 21 MUTATION IN ADVANCED NSCLC: A PHASE-IV, OPEN-LABEL, SINGLE-ARM STUDYHan, B. / Shi, C. / Qian, J. / Li, R. et al. | 2015
- i38
-
123P OUTCOMES OF OCTOGENARIAN (?80 YO) PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SINGLE INSTITUTION EXPERIENCE FROM THE CHRISTIE HOSPITALHowell, M. / Chiramel, J. / Flaum, N. / Lewis, A. / Summers, Y. / Taylor, P. / Chittalia, A. / Sheikh, H. / Blackhall, F. H. et al. | 2015
- i38
-
121P SERUM CARCINOEMBRYONIC ANTIGEN LEVELS PREDICTS THE EFFICACY OF EGFR-TKI IN NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONSZhang, Y. / Han, B. / Jin, B. / Lou, Y. / Li, R. / Zhang, X. / Hu, S. et al. | 2015
- i39
-
126P OUTCOMES OVER A DECADE IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC): THE CLATTERBRIDGE CANCER CENTRE EXPERIENCEEscriu, C. / Wong, H. / Marshall, E. et al. | 2015
- i39
-
128P COMPARISON OF EFFICACY OF PEMETREXED PLUS PLATINUM AND NON-PEMETREXED PLUS PLATINUM AS 1ST LINE CHEMOTHERAPY IN EGFR WILD TYPE NON-SQUAMOUS NSCLCKang, E. J. / Lee, S. Y. / Kim, J. S. et al. | 2015
- i39
-
125P A PROSPECTIVE RANDOMIZED PHASE III STUDY OF PALLIATIVE CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: SURVIVAL ANALYSIS AND ECOG PERFORMANCE STATUS REGRESSION ANALYSISKumar, N. / Kapoor, A. / Kalwar, A. / Narayan, S. / Singhal, M. K. / Kumar, A. / Lal, S. / Nirban, R. K. / Paramanandhan, M. / Purohit, R. et al. | 2015
- i39
-
127P A PROSPECTIVE RANDOMIZED PHASE III STUDY EVALUATING QUALITY OF LIFE IN ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PLATINUM BASED CHEMOTHERAPY COMBINATION IN OLD VERSUS NEW STANDARD CHEMOTHERAPY REGIMENRungta, A. / Kapoor, A. / Dutta, S. et al. | 2015
- i40
-
131P DURATION AND TOLERANCE OF MAINTENANCE PEMETREXED (MPEM) TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCERCharlton, P. / Josephides, E. / Karapanagiotou, E. / Montes, A. / Spicer, J. / Lal, R. et al. | 2015
- i40
-
132P WEEKLY CARBOPLATIN AND PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER: GOOD RESPONSE RATE BUT POOR OVERALL SURVIVAL IN A REAL WORLD POPULATIONMark, M. / Volk, V. / Mey, U. / Brossart, P. / von Moos, R. / Cathomas, R. et al. | 2015
- i40
-
130P MAINTENANCE PEMETEREXED IN NSCLC - OUTCOME ANALYSIS FROM A TERTIARY CARE CENTERPandey, A. V. / Prabhash, K. / Noronha, V. / Joshi, A. et al. | 2015
- i40
-
129P EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCERBrand�o, M. D. / Luis, M. S. / Amaral, N. C. / Cassiano Neves, M. / Camacho, C. / Rodrigues, A. C. / Pousa, I. / Oliveira, J. / Azevedo, I. et al. | 2015
- i41
-
134P EFFECT OF HAEMATOLOGICAL ADVERSE EFFECTS OCCURING DURING CHEMOTHERAPY ON RESPONSE TO TREATMENT AND PROGRESSION FREE SURVIVAL IN ADVANCED NSCLCNagy, A. A. / Fouad, E. / Nasr, K. / El-Ghazaly, H. / Adel, A. et al. | 2015
- i41
-
133P AN ESTIMATION OF THE POPULATION-BASED SURVIVAL BENEFIT OF FIRST-LINE CHEMOTHERAPY FOR LUNG CANCERDo, V. / Ng, W. / Jacob, S. / Delaney, G. / Barton, M. et al. | 2015
- i41
-
136P TTF1 EXPRESSION IN ADVANCED NON-SMALL CELL LUNG CANCER: IMPACT ON SURVIVAL OUTCOMEElsamany, S. / Al-fayea, T. / Abozeed, W. N. / Alzahrani, A. / Farooq, M. U. / Darwish, W. / Almadani, A. / Bukhari, E. et al. | 2015